Methods of reducing mislocalization of an analyte
By embedding biological samples in a porous hydrogel and using capture probes, the method addresses transcript mislocalization in spatial transcriptomics, improving data resolution and accuracy in gene expression analysis.
Patent Information
- Application Number
- PCT/US2024/029893
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
Current spatial transcriptomics methods suffer from transcript mislocalization due to passive migration of analytes, leading to reduced resolution, accuracy, and sensitivity in gene expression data, which affects correct registration of spatial information and cell type identification.
Embedding or coating biological samples in a porous hydrogel to create a biological sample/hydrogel complex, followed by permeabilization and hybridization with capture probes, which limits molecule movement and enhances analyte capture and localization.
This approach reduces transcript mislocalization, improving the resolution and accuracy of spatial data by ensuring analytes interact with proximal capture probes, thereby enhancing the quality of gene expression and cell type identification.
Smart Images

Figure US2024029893_21112024_PF_FP_ABST
Abstract
Description
[0001] METHODS OF REDUCING MISLOCALIZATION OF AN ANALYTE
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 467,135, filed on May 17, 2023, the contents of which are hereby incorporated by reference.
[0004] BACKGROUND
[0005] Cells within a tissue of a subject have differences in cell morphology and / or function due to varied analyte levels (e.g., gene and / or protein expression) within the different cells. The specific position of a cell within a tissue (e.g., the cell’s position relative to neighboring cells or the cell’s position relative to the tissue microenvironment) can affect, e.g., the cell’s morphology, differentiation, fate, viability, proliferation, behavior, and signaling and crosstalk with other cells in the tissue.
[0006] Spatial heterogeneity has been previously studied using techniques that only provide data for a small handful of analytes in the context of an intact tissue or a portion of a tissue, or provide substantial analyte data for dissociated tissue (i.e., single cells), but fail to provide information regarding the position of the single cell in a parent biological sample (e.g.. tissue sample).
[0007] The present disclosure provides methods for mitigating transcript mislocalization (TML) from a tissue or cell by embedding or coating a tissue in hydrogel, thereby decreasing TML and / or resulting in higher resolution analyte expression data in a biological sample.
[0008] SUMMARY
[0009] Spatial transcriptomics (ST) can be used to reduce a three-dimensional (3D) distribution of molecules within a sample into a two-dimensional (2D) image. To do so, a 2D image can be obtained by capturing target molecules that migrate vertically from their original location (e.g., such as within a tissue sample) onto a spatially tagged slide or array. Migration of molecules is typically a passive event, and analytes can migrate in non-vertical directions thereby resulting in a reduction of resolution, accuracy, and / or sensitivity. Mitigating such transcript mislocalization (e.g., diffusion, flow, convection based) would have an impact on the quality of spatial data. Transcript mislocalization (TML) results in incorrect registration of spatial information which leads to incorrect detection of gene expression and potentially cell type identification in spatial data. Described herein are methods that can reduce mislocalization of an analyte in a biological sample, wherein such methods can provide improved binding or capture of the target analyte.
[0010] Thus, included herein are methods for identifying a location of an analyte in a biological sample, the method comprising: (a) contacting the biological sample with a substrate, wherein the substrate comprises a plurality of capture probes, and wherein at least one capture probe of the plurality of capture probes compnses a capture domain and a spatial barcode; (b) forming a porous hydrogel within or surrounding the biological sample, thereby embedding the biological sample in the porous hydrogel or coating the biological sample with the porous hydrogel, thereby generating a biological sample / hydrogel complex; (c) permeabilizing the biological sample / hydrogel complex; (d) hybridizing the analyte, or a proxy thereof, to the capture domain of the at least one capture probe; and (e) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte, or a proxy thereof, from the biological sample, or a complement thereof, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample.
[0011] In some embodiments, the forming step (b) comprises contacting the biological sample with at least one monomer and at least one catalyst. In some embodiments, the biological sample is contacted with the at least one monomer for a period from about 5 minutes to about 1 hour prior to providing the at least one catalyst. In some embodiments, the forming step (b) further comprises contacting the biological sample with the at least one catalyst for a period from about 5 seconds to about 16 hours. In some embodiments, the forming step (b) comprises: (i) soaking the biological sample with at least one monomer; and (ii) polymerizing the at least one monomer in the presence of at least one catalyst. In some embodiments, the biological sample is contacted with the at least one monomer and the at least one catalyst simultaneously for a period from about 5 seconds to about 16 hours. In some embodiments, the forming step (b) comprises: (i) coating the biological sample with at least one monomer and at least one catalyst; and (ii) polymerizing the at least one monomer in the presence of the at least one catalyst.
[0012] In some embodiments, the at least one monomer is provided in the presence of a second monomer that is different than the at least one monomer. In some embodiments, the at least one monomer and / or the second monomer, if present, is provided as a monomer solution at a concentration of about 2% to about 25% in a solvent. In some embodiments, the at least one monomer and / or the second monomer, if present, comprises an acrylamide, a bisacrylamide, an acrylate, a methacrylate, a bis-acrylate, an alginate, a glutaraldehyde, an agarose, or a combination thereof. In some embodiments, the at least one monomer and / or the second monomer, if present, is polymerized by at least one catalyst.
[0013] In some embodiments, the at least one catalyst is provided in the presence of a second catalyst that is different than the at least one catalyst. In some embodiments, the at least one catalyst and / or the second catalyst, if present, is provided as an accelerator solution at a concentration of about 0.01% to about 10% in a solvent. In some embodiments, the at least one catalyst and / or the second catalyst, if present, comprises a free radical initiator, a redox molecule, an adjunct catalyst, or a combination thereof. In some embodiments, the at least one catalyst and / or the second catalyst, if present, comprises a halogen, an azo compound, a peroxide, a peroxy disulfate (e.g., ammonium persulfate (APS) or potassium persulfate (KPS)), an amine (e.g., tetramethylethylenediamine (TEMED) or dimethylaminopropionitrile (DMPN)), or a combination thereof.
[0014] In some embodiments, the polymerization comprises ammonium persulfate (APS) initiator / tetramethylethylenediamine (TEMED)-based crosslinking. In some embodiments, the polymerization comprises Azo initiator-based crosslinking. In some embodiments, the polymerization comprises UV-based crosslinking.
[0015] In some embodiments, the porous hydrogel is a non-degradable hydrogel. In some embodiments, the non-degradable hydrogel comprises a non-cleavable linker (e.g., a polymerized form of bis-acrylamide). In some embodiments, the porous hydrogel is a degradable hydrogel. In some embodiments, the degradable hydrogel comprises a cleavable linker (e.g., a polymerized form of cystamine bis-acrylamide).
[0016] In some embodiments, the method further comprises after the permeabilizing step (c) or the capturing step (d) contacting the degradable hydrogel with a cleaving agent. In some embodiments, the cleaving agent comprises a reducing agent, wherein the reducing agent is dithiothreitol (DTT).
[0017] In some embodiments, the forming step (b) comprises incubating the biological sample with the at least one monomer in the presence of at least one catalyst to polymerize the at least one monomer.
[0018] In some embodiments, the permeabilizing step (c) comprises contacting the porous hydrogel with a permeabilization agent. In some embodiments, the permeabilization agent comprises proteinase K. In some embodiments, the permeabilization agent is provided in the presence of a buffer, a surfactant, a polyethylene glycol (PEG), or a combination thereof. In some embodiments, the permeabilizing step (c) further comprises removing the permeabilized biological sample from the substrate. In some embodiments, the method further comprises one or more of the following: (i) contacting the substrate with a bind-silane solution prior to contacting step (a); (ii) contacting the biological sample with an acrylic acid ester prior to or after contacting step (a); (iii) destaining the biological sample, wherein the biological sample is previously stained prior to or after contacting step (a); and / or (iv) washing the biological sample with phosphate buffered saline with Tween™ 20 prior to or after forming step (b).
[0019] Also provided herein are methods of reducing mislocalization of an analyte in a biological sample, the method comprising: (a) providing the biological sample on a substrate, wherein the substrate comprises a plurality of capture probes, and wherein at least one capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode; (b) contacting the biological sample with at least one monomer; (c) polymerizing the at least one monomer in the presence of at least one catalyst to form a porous hydrogel within or surrounding the biological sample, thereby generating an embedded biological sample in the porous hydrogel or coating the biological sample with the porous hydrogel, thereby generating a coated biological sample; and (d) permeabilizing the embedded biological sample or the coated biological sample to remove at least a portion of the biological sample and to allow- the analyte, or a proxy thereof, in the biological sample to interact with the at least one capture probe of the plurality of capture probes, thereby reducing mislocalization of the analyte in the biological sample.
[0020] In some embodiments, the method further comprises: (e) extending the at least one capture probe using the analyte, or a proxy thereof, as a template; and (f) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte, or the proxy thereof, from the biological sample or a complement thereof, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample.
[0021] In some embodiments, the method further comprises: (e) hybridizing a ligation product to the at least one capture probe, wherein the ligation product comprises a sequence that is substantially complementary to a sequence of the analyte in the biological sample; and (f) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte from the biological sample, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample.
[0022] Also provided herein are methods for identifying a location of an analyte in a biological sample, the method comprising: (a) contacting the biological sample with a first substrate; (b) forming a porous hydrogel within or surrounding the biological sample, thereby embedding the biological sample in the porous hydrogel or coating the biological sample with the porous hydrogel; (c) aligning the first substrate with a second substrate comprising an array, such that at least a portion of the biological sample is aligned with at least a portion of the array, wherein the array comprises a plurality of capture probes, wherein at least one capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode; (d) capturing the analyte, or a proxy thereof, using the at least one capture probe when the biological sample is aligned with at least a portion of the array; and (e) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte, or a proxy thereof, from the biological sample, or a complement thereof, and using the determined sequences of (i) and (ii) to identity' the location of the analyte in the biological sample.
[0023] In some embodiments, the capturing step (d) further comprises migrating the analyte, or the proxy thereof, from the biological sample to the array.
[0024] In some embodiments, the aligning step (c) comprises: mounting the first substrate on a first member of a support device, the first member configured to retain the first substrate; mounting the second substrate on a second member of the support device; applying a reagent medium to the first substrate and / or the second substrate; and operating an alignment mechanism of the support device to move the first member and / or the second member such that at least a portion of the biological sample is aligned with at least a portion of the array, and such that the portion of the biological sample and the portion of the array contact the reagent medium. In some embodiments, the alignment mechanism is coupled to the first member, the second member, or both the first member and the second member. In some embodiments, the alignment mechanism comprises a linear actuator, and optionally wherein: the linear actuator is configured to move the second member along an axis orthogonal to the plane or the first member and / or the second member, and / or the linear actuator is configured to move the first member along an axis orthogonal to the plane of the first member and / or the second member, and / or the linear actuator is configured to move the first member, the second member, or both the first member and the second member at a velocity' of at least 0. 1 mm / sec, and / or the linear actuator is configured to move the first member, the second member, or both the first member and the second member with an amount of force of at least 0. 1 lbs.
[0025] In some embodiments, at least one of the first substrate and the second substrate further comprise a spacer disposed on the first substrate or the second substrate, wherein when at least the portion of the biological sample is aligned with at least a portion of the array such that the portion of the biological sample and the portion of the array contact the reagent medium, the spacer is disposed between the first substrate and the second substrate and is configured to maintain the reagent medium within a chamber formed by the first substrate, the second substrate, and the spacer, and to maintain a separation distance between the first substrate and the second substrate, wherein the spacer is positioned to surround an area on the first substrate on which the biological sample is disposed and / or the array disposed on the second substrate, wherein the area of the first substrate, the spacer, and the second substrate at least partially encloses a volume comprising the biological sample.
[0026] In some embodiments, the capturing step (d) comprises contacting the biological sample with a reagent medium comprising a permeabilization agent, thereby permeabilizing the biological sample to allow the analyte, or the proxy thereof, in the biological sample to interact with the array. In some embodiments, the permeabilization agent comprises a protease. In some embodiments, the permeabilization agent is provided in the presence of a buffer, a surfactant, a polyethylene glycol (PEG), or a combination thereof.
[0027] Also provided herein are kits comprising: (a)a spatial array comprising a plurality of capture probes, wherein at least one capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode; (b) a first reagent medium comprising at least one monomer configured to be polymerized, thereby forming a porous hydrogel; (c) a second reagent medium comprising at least one catalyst configured to catalyze a polymerization reaction for forming the porous hydrogel; (d) a third reagent medium comprising a permeabilization agent; and (e) instructions for performing any one of the methods described herein.
[0028] In some embodiments, the kit further comprises: (!) a support device configured to retain a first substrate and a second substrate, wherein the biological sample is placed on the first substrate, and wherein the second substrate comprises the spatial array; and (g) an optional alignment mechanism on the support device to align the first substrate and the second substrate.
[0029] In some embodiments, the at least one monomer comprises an acrylamide, a bisacrylamide, an acrylate, a methacrylate, a bis-acrylate, an alginate, a glutaraldehyde, an agarose, or a combination thereof. In some embodiments, the at least one monomer is provided as a monomer solution at a concentration of about 2% to about 25% in a solvent.
[0030] In some embodiments, the at least one catalyst comprises a free radical initiator, a redox molecule, an adjunct catalyst, or a combination thereof. In some embodiments, the at least one catalyst comprises a halogen, an azo compound, a peroxide, a peroxy disulfate (e.g., ammonium persulfate (APS) or potassium persulfate (KPS)), an amine (e.g., tetramethylethylenediamine (TEMED) or dimethylaminopropionitrile (DMPN)). or a combination thereof. In some embodiments, the at least one catalyst is provided as an accelerator solution at a concentration of about 0.01% to about 10% in a solvent.
[0031] Where values are described in terms of ranges, it should be understood that the description includes the disclosure of all possible sub-ranges within such ranges, as well as specific numerical values that fall within such ranges irrespective of whether a specific numerical value or specific sub-range is expressly stated. The term “about” or “approximately” as used herein means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within an acceptable standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to ±20%. preferably up to ±10%, more preferably up to ±5%, and more preferably still up to ±1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated, the term “about” is implicit and in this context means within an acceptable error range for the particular value.
[0032] The term “substantially complementary” used herein means that a first sequence is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the complement of a second sequence over a region of 2, 3, 4, 5, 6, 7. 8, 9, 10, 11, 12, 13, 14, 15. 16, 17, 18, 19, 20-40, 40-60. 60-100, or more nucleotides, or that the two sequences hybridize under stringent hybridization conditions. Substantially complementary also means that a sequence in one strand is not necessarily completely and / or perfectly complementary' to a sequence in an opposing strand, but that sufficient bonding occurs between bases on the two strands to form a stable hybrid complex in set of hybridization conditions (e.g.. salt concentration and temperature). Such conditions can be predicted by using the sequences and standard mathematical calculations known to those skilled in the art.
[0033] The term “each,” w hen used in reference to a collection of items, is intended to identify an individual item in the collection but does not necessarily refer to every item in the collection, unless expressly stated otherwise, or unless the context of the usage clearly indicates otherwise.
[0034] Various embodiments of the features of this disclosure are described herein. How ever, it should be understood that such embodiments are provided merely by way of example, and numerous variations, changes, and substitutions can occur to those skilled in the art without departing from the scope of this disclosure. It should also be understood that various alternatives to the specific embodiments described herein are also within the scope of this disclosure.
[0035] DESCRIPTION OF DRAWINGS
[0036] The following drawings illustrate certain embodiments of the features and advantages of this disclosure. These embodiments are not intended to limit the scope of the appended claims in any manner. Like reference symbols in the drawings indicate like elements.
[0037] FIG. 1A shows an exemplary sandwiching process where a first substrate (e.g., a slide), including a biological sample, and a second substrate (e.g., array slide) are brought into proximity with one another.
[0038] FIG. IB shows a fully formed sandwich configuration creating a chamber formed from the one or more spacers, the first substrate, and the second substrate.
[0039] FIG. 2A shows a perspective view of an exemplary sample handling apparatus in a closed position.
[0040] FIG. 2B shows a perspective view of an exemplary sample handling apparatus in an open position.
[0041] FIG. 3A shows the first substrate angled over (superior to) the second substrate.
[0042] FIG. 3B shows that as the first substrate lowers, and / or as the second substrate rises, the dropped side of the first substrate may contact a drop of reagent medium.
[0043] FIG. 3C shows a full closure of the sandwich between the first substrate and the second substrate with one or more spacers contacting both the first substrate and the second substrate.
[0044] FIG. 4A shows a side view of the angled closure workflow.
[0045] FIG. 4B shows a top view of the angled closure workflow.
[0046] FIG. 5 is a schematic diagram showing an example of a barcoded capture probe, as described herein.
[0047] FIG. 6 shows a schematic illustrating a cleavable capture probe.
[0048] FIG. 7 shows exemplary7capture domains on capture probes.
[0049] FIG. 8 shows an exemplar}7arrangement of barcoded features within an array.
[0050] FIG. 9A shows and exemplary workflow for performing a templated capture and producing a ligation product, and FIG. 9B shows an exemplary workflow for capturing a ligation product from FIG. 9 A on a substrate.
[0051] FIG. 10 shows a first exemplar7method describing hydrogel / tissue interaction. FIG. 11 shows a second exemplary method describing hydrogel / tissue interaction.
[0052] FIG. 12 shows an experimental set up on a spatial arrayed slide for biological samples embedded in non-degradable hydrogels with variable permeabilization times. n=2 for each permeabilization exposure time including control.
[0053] FIG. 13 shows exemplary7fluorescent images of cDNA fluorescent footprints from experiments run using the experimental set up in FIG. 12 using mouse brain tissues embedded in non-degradable hydrogels. Exposure time was 200ms. Arrows identify the hippocampus.
[0054] FIG. 14 shows magnified areas of the images found in FIG. 13 comparing cDNA footprint fluorescence to data from a puncta fluorescent assay targeting the Prox 1 gene. Arrows identify the hippocampus.
[0055] FIG. 15 shows an experimental set up on a spatial arrayed slide for biological samples embedded in nondegradable hydrogel with variable permeabilization times, with or without PEG in the permeabilization buffer. n=2 for each condition including control.
[0056] FIG. 16 shows exemplary images of experiments run using the experimental set up as found in FIG. 15, using fresh frozen mouse brain tissue sections embedded in non- degradable hydrogel, with or without the addition of PEG in the permeabilization buffer. Arrows identify the hippocampus.
[0057] FIG. 17 shows an experimental set up on a spatial arrayed slide for biological tissues embedded in hydrogel and permeabilization buffer with or without PEG.
[0058] FIG. 18 shows exemplary images using the experimental set up of FIG. 17 showing cDNA footprint fluorescence. Arrows indicate hippocampus.
[0059] DETAILED DESCRIPTION
[0060] The migration of analytes from a biological sample to a spatially arrayed slide is typically a passive process, where gravity causes analytes (e.g.. nucleic acid analytes or an intermediate agent thereof) to migrate to a spatial array where they are hybridized to proximal capture domains of capture probes. However, passive migration can allow for mislocalization of analytes, where some of the analytes migrate and hybridize to non-proximal capture probe capture domains. Transcript mislocalization, or TML, can affect the resolution, sensitivity, and specificity of spatially arrayed gene expression data.
[0061] Described herein are methods and compositions that may be used to reduce TML from a biological sample. Without wishing to be limited by mechanism, a gel / polymer based system is proposed herein to provide a physical constraint that limits movement of molecules during permeabilization of the biological sample, thereby controlling migration of target molecules in a downw ard manner so they interact with proximal capture probes instead of non-proximal capture probes, thereby minimizing transcript mislocalization. In some embodiments, the analyte can be a nucleic acid such as a mRNA or DNA, or the analytes can be an intermediate agent (e.g., a ligation product, such as any described herein) that is a proxy for a target analyte.
[0062] A. Spatial Analysis Methods
[0063] Spatial analysis methodologies described herein can provide a vast amount of analyte and / or expression data for a variety of analytes within a biological sample at high spatial resolution, while retaining native spatial context. Spatial analysis methods can include, e.g., the use of a capture probe including a spatial barcode (e.g., a nucleic acid sequence that provides information as to the location or position of an analyte within a cell or a tissue sample (e.g., mammalian cell or a mammalian tissue sample) and a capture domain that is capable of binding to an analyte (e.g., a protein and / or a nucleic acid) produced by and / or present in a cell. Spatial analysis methods and compositions can also include the use of a capture probe having a capture domain that captures an intermediate agent for indirect detection of an analyte. For example, the intermediate agent can include a nucleic acid sequence (e.g., a barcode) associated with the intermediate agent. Detection of the intermediate agent is therefore indicative of the analyte in the cell or tissue sample.
[0064] Non-limiting aspects of spatial analysis methodologies and compositions are described in U.S. Patent Nos. 11,447,807, 11,352,667, 11,168,350, 11,104,936, 11,008,608, 10,995,361, 10,913,975, 10,774,374, 10,724,078, 10,640,816, 10,494,662, 10,480,022, 10,364.457, 10,317,321, 10,059,990, 10,041,949, 10,030,261, 10.002,316, 9,879,313, 9,783,841, 9.727,810, 9,593.365, 8,951,726, 8,604,182. and 7,709,198; U.S. Patent Application Publication Nos. 2020 / 0239946, 2020 / 0080136, 2020 / 0277663, 2019 / 0330617, 2020 / 0256867, 2020 / 0224244, 2019 / 0085383, and 2013 / 0171621; PCT Publication Nos. WO2018 / 091676, W02020 / 176788, WO2017 / 144338, and WO2016 / 057552; Non-patent literature references Rodriques et al., Science 363(6434): 1463-1467, 2019; Lee et al., Nat. Protoc. 10(3):442-458. 2015; Trejo et al., PLoS ONE 14(2) :e0212031, 2019; Chen et al.. Science 348(6233):aaa6090, 2015; Gao et al., BMC Biol. 15:50, 2017; and Gupta et al., Nature Biotechnol. 36:1197-1202, 2018; and the Visium Spatial Gene Expression Reagent Kits User Guide (e.g., Rev F, dated January 2022) and / or the Visium Spatial Gene Expression Reagent Kits - Tissue Optimization User Guide (e.g., Rev E, dated February 2022), both of which are available at the lOx Genomics Support Documentation website, and can be used herein in any combination, and each of which is incorporated herein by reference in its entirety. Further non-limiting aspects of spatial analysis methodologies and compositions are described herein.
[0065] Some general terminology that may be used in this disclosure can be found in Section (I)(b) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference. Typically, a "barcode" is a label, or identifier, that conveys or is capable of conveying information (e.g., information about an analyte in a sample, a bead, and / or a capture probe). A barcode can be part of an analyte, or independent of an analyte. A barcode can be attached to an analyte. A particular barcode can be unique relative to other barcodes. For the purpose of this disclosure, an “analyte” can include any biological substance, structure, moiety, or component to be analyzed. The term “target” can similarly refer to an analyte of interest.
[0066] Analytes can be broadly classified into one of two groups: nucleic acid analytes and non-nucleic acid analytes. Examples of non-nucleic acid analytes include, but are not limited to, lipids, carbohydrates, peptides, proteins, glycoproteins (N-linked or O-linked), lipoproteins, phosphoproteins, specific phosphorylated or acetylated variants of proteins, amidation variants of proteins, hydroxylation variants of proteins, methylation variants of proteins, ubiquitylation variants of proteins, sulfation variants of proteins, viral proteins (e g., viral capsid, viral envelope, viral coat, viral accessory', viral glycoproteins, viral spike, etc.), extracellular and intracellular proteins, antibodies, and antigen binding fragments. In some embodiments, the analyte(s) can be localized to subcellular location(s), including, for example, organelles, e.g., mitochondria, Golgi apparatus, endoplasmic reticulum, chloroplasts, endocytic vesicles, exocytic vesicles, vacuoles, lysosomes, etc. In some embodiments, analyte(s) can be peptides or proteins, including without limitation antibodies and enzymes. Additional examples of analytes can be found in Section (I)(c) of PCT Publication No. WO2020 / I76788 and / or U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference. In some embodiments, an analyte can be detected indirectly, such as through detection of an intermediate agent, for example, a ligation product or an analyte capture agent (e.g., an oligonucleotide-conjugated antibody), such as those described herein. A “biological sample” is typically obtained from the subject for analysis using any of a variety of techniques including, but not limited to. biopsy, surgery’, and laser capture microscopy (LCM), and generally includes cells and / or other biological material from the subject. In some embodiments, the biological sample is a tissue sample. In some embodiments, the biological sample (e.g., tissue sample) is a tissue microarray (TMA). A tissue microarray contains multiple representative tissue samples - which can be from different tissues or organisms - assembled on a single histologic slide. The TMA can therefore allow for high throughput analysis of multiple specimens at the same time. Tissue microarrays may be paraffin blocks produced by extracting cylindrical tissue cores from different paraffin donor blocks and re-embedding these tissue cores into a single recipient (microarray) block at defined array coordinates.
[0067] The biological sample as used herein can be any suitable biological sample described herein or known in the art. In some embodiments, the biological sample is a tissue sample. In some embodiments, the tissue sample is a solid tissue sample. In some embodiments, the biological sample is a tissue section (e.g., a fixed tissue section). In some embodiments, the tissue is flash-frozen and sectioned. Any suitable method described herein or known in the art can be used to flash-freeze and section the tissue sample. In some embodiments, the biological sample, e.g., the tissue, is flash-frozen using liquid nitrogen before sectioning. In some embodiments, the biological sample, e.g., a tissue sample, is flash-frozen using nitrogen (e.g.. liquid nitrogen), isopentane, or hexane.
[0068] In some embodiments, the biological sample, e.g., the tissue, is embedded in a matrix e.g., optimal cutting temperature (OCT) compound to facilitate sectioning. OCT compound is a formulation of clear, water-soluble glycols and resins, providing a solid matrix to encapsulate biological (e.g., tissue) specimens. In some embodiments, the sectioning is performed by cryosectioning, for example using a microtome. In some embodiments, the methods further comprise a thawing step, after the cryosectioning.
[0069] The biological sample can be from a mammal. In some instances, the biological sample is from a human, mouse, or rat. In addition to the subjects described above, the biological sample can be obtained from non-mammalian organisms (e.g.. a plant, an insect, an arachnid, a nematode (e.g., Caenorhabditis elegans), a fungus, an amphibian, or a fish (e.g., zebrafish)). A biological sample can be obtained from a prokar ote such as a bacterium, e.g., Escherichia coll. Staphylococci or Mycoplasma pneumoniae,' an archaeon; a virus such as Hepatitis C virus or human immunodeficiency virus; or a viroid. A biological sample can be obtained from a eukaryote, such as a patient derived organoid (PDO) or patient derived xenograft (PDX). The biological sample can include organoids, a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic micro-anatomy. Organoids can be generated from one or more cells from a tissue, embryonic stem cells, and / or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities. In some embodiments, an organoid is a cerebral organoid, an intestinal organoid, a stomach organoid, a lingual organoid, a thyroid organoid, a thymic organoid, a testicular organoid, a hepatic organoid, a pancreatic organoid, an epithelial organoid, a lung organoid, a kidney organoid, a gastruloid, a cardiac organoid, or a retinal organoid. Subjects from which biological samples can be obtained can be healthy or asymptomatic individuals, individuals that have or are suspected of having a disease (e.g.. cancer) or a pre-disposition to a disease, and / or individuals that are in need of therapy or suspected of needing therapy.
[0070] Biological samples can be derived from a homogeneous culture or population of the subjects or organisms mentioned herein or alternatively from a collection of several different organisms, for example, in a community or ecosystem.
[0071] Biological samples can include one or more diseased cells. A diseased cell can have altered metabolic properties, gene expression, protein expression, and / or morphologic features. Examples of diseases include inflammatory disorders, metabolic disorders, nervous system disorders, and cancer. Cancer cells can be derived from solid tumors, hematological malignancies, cell lines, or obtained as circulating tumor cells.
[0072] In some embodiments, the biological sample, e.g., the tissue sample, is fixed in a fixative including alcohol, for example, methanol. In some embodiments, instead of methanol, acetone or an acetone-methanol mixture can be used. In some embodiments, the fixation is performed after sectioning. In some instances, when the biological sample is fixed using a fixative including an alcohol (e.g., methanol or acetone-methanol mixture), the biological sample is not decrosslinked afterward. In some preferred embodiments, the biological sample is fixed using a fixative including an alcohol (e.g., methanol or an acetone- methanol mixture) after freezing and / or sectioning. In some instances, the biological sample is flash-frozen, and then the biological sample is sectioned and fixed (e.g., using methanol, acetone, or an acetone-methanol mixture). In some instances when methanol, acetone, or an acetone-methanol mixture is used to fix the biological sample, the sample is not decrosslinked at a later step. In instances when the biological sample is frozen (e.g., flash frozen using liquid nitrogen and embedded in OCT) followed by sectioning and alcohol (e.g., methanol, acetone-methanol) fixation or acetone fixation, the biological sample is referred to as “fresh frozen’". In some embodiments, fixation of the biological sample, e.g., using acetone and / or alcohol (e.g., methanol, acetone-methanol), is performed while the sample is mounted on a substrate (e.g., glass slide, such as a positively charged glass slide).
[0073] In some embodiments, the biological sample, e.g., the tissue sample, is fixed e.g., immediately after being harvested from a subject. In such embodiments, the fixative is preferably an aldehyde fixative, such as paraformaldehyde (PF A) or formalin. In some embodiments, the fixative induces crosslinks within the biological sample. In some embodiments, after fixing, e g., by formalin or PF A, the biological sample is dehydrated via sucrose gradient. In some instances, the fixed biological sample is treated with a sucrose gradient and then embedded in a matrix, e.g., OCT compound. In some instances, the fixed biological sample is not treated with a sucrose gradient, but rather is embedded in a matrix, e.g., OCT compound after fixation. In some embodiments when a fixed frozen tissue sample is treated with a sucrose gradient, the sample can be rehydrated using an ethanol gradient. In some embodiments, the PFA or formalin fixed biological sample, which can be optionally dehydrated via sucrose gradient and / or embedded in OCT compound, is then frozen, e.g., for storage or shipment. In such instances, the biological sample is referred to as “fixed frozen”. In preferred embodiments, a fixed frozen biological sample is not treated with methanol. In preferred embodiments, a fixed frozen biological sample is not paraffin embedded. Thus, in preferred embodiments, a fixed frozen biological sample is not deparaffinized. In some embodiments, a fixed frozen biological sample is rehydrated using an ethanol gradient.
[0074] In some instances, the biological sample (e g., a fixed frozen tissue sample) is treated with a citrate buffer. Citrate buffer can be used to decrosslink antigens and fixation medium for antigen retrieval in the biological sample. Thus, any suitable decrosslinking agent can be used in addition, or alternatively, to citrate buffer. In some embodiments, for example, the biological sample (e.g., a fixed frozen tissue sample) is decrosslinked using TE buffer.
[0075] In any of the foregoing, the biological sample can further be stained, imaged, and / or destained. For example, in some embodiments, a fresh frozen tissue sample or fixed frozen tissue sample is stained (e.g., via eosin and / or hematoxylin), imaged, destained (e.g., via HC1). or a combination thereof. In some embodiments, when a fresh frozen tissue sample is fixed in methanol, the sample is treated with isopropanol prior to being stained (e.g., via eosin and / or hematoxylin), imaged, destained (e.g., via HC1), or a combination thereof. In some embodiments when a fixed frozen tissue sample is treated with a sucrose gradient, the sample can be rehydrated using an ethanol gradient before being stained, (e.g., via eosin and / or hematoxylin), imaged, destained (e.g., via HC1), decrosslinked (e.g., via TE buffer or citrate buffer), or a combination thereof. In some embodiments, the biological sample can undergo further fixation (e.g., while mounted on a substrate), stained, imaged, and / or destained. For example, a fixed frozen biological sample may be subject to an additional fixing step (e.g., using PF A) before optional ethanol rehydration, staining, imaging, and / or destaining.
[0076] In any of the foregoing, the biological sample can be fixed using PAXgene. For example, the biological sample can be fixed using PAXgene in addition, or alternatively to, a fixative disclosed herein or known in the art (e g., alcohol, acetone, acetone-alcohol, formalin, paraformaldehyde). PAXgene is a non-cross-linking mixture of different alcohols, an acid, and a soluble organic compound that preserves morphology and biomolecules. PAXgene provides a two-reagent fixative system in which tissue is firstly fixed in a solution containing methanol and acetic acid, then stabilized in a solution containing ethanol. See, Ergin B. et al., J Proteome Res. 2010 Oct 1 ;9(10):5188-96; Kap M. et al., PLoS One.; 6(l l):e27704 (2011); and Mathieson W. et al., Am J Clin Pathol.; 146(l):25-40 (2016), each of which is hereby incorporated by reference in its entirety, for a description and evaluation of PAXgene for tissue fixation. Thus, in some embodiments, when the biological sample, e.g., the tissue sample, is fixed in a fixative including alcohol, the fixative is PAXgene. In some embodiments, a fresh frozen tissue sample is fixed with PAXgene. In some embodiments, a fixed frozen tissue sample is fixed with PAXgene.
[0077] In some embodiments, the biological sample, e.g.. the tissue sample, is fixed, for example in methanol, acetone, acetone-methanol, PF A, PAXgene, or is formalin-fixed and paraffin-embedded (FFPE). In some embodiments, the biological sample comprises intact cells. In some embodiments, the biological sample is a cell pellet, e.g., a fixed cell pellet, e.g., an FFPE cell pellet. FFPE samples are used in some instances in the RNA-templated ligation (RTL) methods disclosed herein. A limitation of direct RNA capture for fixed samples is that the RNA integrity of fixed (e.g., FFPE) samples can be lower than of a fresh sample, thereby capturing RNA directly from fixed samples, e.g., by capture of a common sequence such as a poly(A) tail of an mRNA molecule, can be more difficult. By utilizing RTL probes that hybridize to RNA target sequences in the transcriptome. RNA analytes can be captured without requiring that both a poly(A) tail and target sequences remain intact. Accordingly, RTL probes can be utilized to beneficially improve capture and spatial analysis of fixed samples. The biological sample, e.g., tissue sample, can be stained, and imaged prior, during, and / or after each step of the methods described herein. Any of the methods described herein or known in the art can be used to stain and / or image the biological sample. In some embodiments, the imaging occurs prior to destaining the sample. In some embodiments, the biological sample is stained using an H&E staining method. In some embodiments, the tissue sample is stained and imaged for about 10 minutes to about 2 hours (or any of the subranges of this range described herein). Additional time may be needed for staining and imaging of different types of biological samples.
[0078] The tissue sample can be obtained from any suitable location in a tissue or organ of a subject, e.g., a human subject. In some instances, the sample is a mouse sample. In some instances, the sample is a human sample. In some embodiments, the sample can be derived from skin, brain, breast, lung, liver, kidney, prostate, tonsil, thymus, testes, bone, lymph node, ovary, eye. heart, or spleen. In some instances, the sample is a human or mouse breast tissue sample. In some instances, the sample is a human or mouse brain tissue sample. In some instances, the sample is a human or mouse lung tissue sample. In some instances, the sample is a human or mouse tonsil tissue sample. In some instances, the sample is a human or mouse liver tissue sample. In some instances, the sample is a human or mouse bone, skin, kidney, thymus, testes, or prostate tissue sample. In some embodiments, the tissue sample is derived from normal or diseased tissue. In some embodiments, the sample is an embryo sample. The embryo sample can be a non-human embryo sample. In some instances, the sample is a mouse embryo sample.
[0079] Biological samples are also described in Section (I)(d) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663. which is herein incorporated by reference.
[0080] The following embodiments can be used with any of the methods described herein. In some embodiments, the biological sample (e.g., a fixed and / or stained biological sample) is imaged. In some embodiments, the biological sample is visualized or imaged using bright field microscopy. In some embodiments, the biological sample is visualized or imaged using fluorescence microscopy. The biological sample can be visualized or imaged using additional methods of visualization and imaging know n in the art. Non-limiting examples of visualization and imaging include expansion microscopy, bright field microscopy, dark field microscopy, phase contrast microscopy, electron microscopy, fluorescence microscopy, reflection microscopy, interference microscopy and confocal microscopy. In some embodiments, the sample is stained and imaged prior to adding reagents for analyzing captured analytes, as disclosed herein, to the biological sample.
[0081] In some embodiments, the methods include staining the biological sample. In some embodiments, the staining includes the use of hematoxylin and / or eosin. Non-limiting examples of stains include histological stains (e.g., hematoxylin and / or eosin) and immunological stains (e.g., fluorescent stains). In some embodiments, a biological sample can be stained using any number of biological stains, including but not limited to, acridine orange, Bismarck brown, carmine, coomassie blue, cresyl violet, DAPI (4',6-diamidino-2- phenylindole), eosin, ethidium bromide, acid fuchsine, hematoxylin, Hoechst stains, iodine, methyl green, methylene blue, neutral red. Nile blue, Nile red, osmium tetroxide, propidium iodide, rhodamine, or safranin. In some instances, the biological sample can be stained using known staining techniques, including Can-Grunwald, Giemsa, hematoxylin and eosin (H&E), Jenner’s, Leishman, Masson’s trichrome, Papanicolaou, Romanowsky7, silver, Sudan, Wright’s, and / or Periodic Acid Schiff (PAS) staining techniques. PAS staining is ty pically performed after formalin or acetone fixation.
[0082] In some embodiments, the staining includes the use of a detectable label, such as a radioisotope, a fluorophore, a chemiluminescent compound, a bioluminescent compound, or a combination thereof.
[0083] In some embodiments, a biological sample is permeabilized with one or more permeabilization reagents. For example, permeabilization of a biological sample can facilitate analyte capture. Exemplary permeabilization agents and conditions are described in Section (I)(d)(ii)(l 3) or the Exemplary' Embodiments Section of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference. Briefly, any of the methods described herein includes permeabilizing the biological sample. For example, the biological sample can be permeabilized to facilitate transfer of extension products to the capture probes on the array. In some embodiments, the permeabilizing includes the use of an organic solvent (e.g., acetone, ethanol, or methanol), a detergent (e.g., saponin, Triton X-I00™, Tween-20™, or sodium dodecyl sulfate (SDS)), an enzyme (e.g., an endopeptidase, an exopeptidase, or a protease), or a combination thereof. In some embodiments, the permeabilizing includes the use of an endopeptidase, a protease, SDS, polyethylene glycol tert-octylphenyl ether, polysorbate 80, polysorbate 20, N-lauroylsarcosine sodium salt solution, saponin, Triton X- 100™, Tween-20™, or a combination thereof. In some embodiments, the endopeptidase is pepsin. In some embodiments, the endopeptidase is Proteinase K. Additional methods for sample permeabilization are described, for example, in Jamur et al., Method Mol. Biol. 588:63-66, 2010. which is herein incorporated by reference.
[0084] Array-based spatial analysis methods can involve the transfer of one or more analytes or derivatives thereof from a biological sample to an array of features on a substrate, where each feature is associated with a unique spatial location on the array. Subsequent analysis of the transferred analytes includes determining the identity of the analytes and the spatial location of the analytes within the biological sample. The spatial location of an analyte within the biological sample is determined based on the feature to which the analyte is bound (e.g., directly or indirectly) on the array, and the feature’s relative spatial location within the array.
[0085] A “capture probe” refers to any molecule capable of capturing (directly or indirectly) and / or labelling an analyte (e.g.. an analyte of interest) in a biological sample. In some embodiments, the capture probe is a nucleic acid or a polypeptide. In some embodiments, the capture probe includes a barcode (e.g., a spatial barcode and / or a unique molecular identifier (UMI) and a capture domain). In some instances, the capture probe includes a homopolymer sequence, such as a poly(T) sequence. In some embodiments, a capture probe can include a cleavage domain and / or a functional domain (e.g., a primer-binding site, such as for nextgeneration sequencing (NGS)). See, e.g., Section (II)(b) (e.g., subsections (i)-(vi)) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663. which is herein incorporated by reference. Generation of capture probes can be achieved by any appropriate method, including those described in Section (II)(d)(ii) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference.
[0086] In some instances, a capture probe and a nucleic acid analyte interaction (or any other nucleic acid to nucleic acid interaction) occurs because the sequences of the two nucleic acids are substantially complementary to one another. By “substantial,” “substantially,” and the like, two nucleic acid sequences can be complementary when at least 60% of the nucleotide residues of one nucleic acid sequence are complementary to nucleotide residues of the other nucleic acid sequence. The complementary residues within a particular complementary- nucleic acid sequence need not always be contiguous with each other, but can be interrupted by one or more non-complementary residues within the complementary nucleic acid sequence. In some embodiments, at least 60%, but less than 100%, of the residues of one of the two complementary- nucleic acid sequences are complementary to residues of the other nucleic acid sequence. In some embodiments, at least 70%. 80%. 90%. 95%. or 99% of the residues of one nucleic acid sequence are complementary to residues of the other nucleic acid sequence. Sequences are said to be “substantially complementary ” when at least 60% (e.g., at least 70%, at least 80%, or at least 90%) of the residues of one nucleic acid sequence are complementary- to residues of the other nucleic acid sequence. In some embodiments, the biological sample is mounted on a first substrate and the substrate comprising the array of capture probes is a second substrate. In this configuration, one or more analytes or analyte derivatives (e.g., intermediate agents; e.g.. ligation products) are then released from the biological sample and migrate to the second substrate comprising an array of capture probes. In some embodiments, the release and migration of the analytes or analyte derivatives to the second substrate comprising the array of capture probes occurs in a manner that preserves the original spatial context of the analytes in the biological sample. This method can be referred to as a sandwiching process, which is described, e.g., in U.S. Patent Application Pub. No. 2021 / 0189475 and PCT Pub. Nos. WO 2021 / 252747 Al, WO 2022 / 061152 A2, and WO 2022 / 140028 Al, each of which is herein incorporated by reference.
[0087] FIG. 1A shows an exemplary' sandwiching process 100 where a first substrate (e.g., slide 103), including a biological sample 102, and a second substrate (e.g., array slide 104 including an array having spatially barcoded capture probes 106) are brought into proximity with one another. As shown in FIG. 1A, a liquid reagent drop (e.g., permeabilization solution 105) is introduced on the second substrate in proximity to the capture probes 106 and in between the biological sample 102 and the second substrate (e.g.. slide 104 including an array having spatially barcoded capture probes 106). The permeabilization solution 105 may release analytes or analyte derivatives (e.g., intermediate agents; e.g., ligation products) that can be captured by the capture probes of the array 106.
[0088] During the exemplary sandwiching process, the first substrate is aligned with the second substrate, such that at least a portion of the biological sample is aligned w ith at least a portion of the capture probes (e g., aligned in a sandwich configuration). As shown, the second substrate (e.g., array slide 104) is in an inferior position to the first substrate (e.g., slide 103). In some embodiments, the first substrate (e.g., slide 103) may be positioned superior to the second substrate (e.g., slide 104). A reagent medium 105 within a gap between the first substrate (e.g., slide 103) and the second substrate (e.g., slide 104) creates a liquid interface between the tw o substrates. The reagent medium may be a permeabilization solution which permeabilizes and / or digests the biological sample 102. In some embodiments wherein the biological sample 102 has been pre-permeabilized, the reagent medium is not a permeabilization solution. Herein, the reagent medium may also comprise one or more of a monovalent salt, a divalent salt, ethylene carbonate, and / or glycerol. In some embodiments, analytes (e.g., mRNA transcripts) and / or analyte derivatives (e.g., intermediate agents; e.g., ligation products) of the biological sample 102 may release from the biological sample, and actively or passively migrate (e.g.. diffuse) across the gap toward the capture probes on the array 106. Alternatively, in certain embodiments, migration of the analyte or analyte derivative (e.g., intermediate agent; e.g.. ligation product) from the biological sample is performed actively (e.g.. electrophoretic, by applying an electric field to promote migration). Exemplary methods of electrophoretic migration are described in WO 2020 / 176788 and U.S. Patent Application Pub. No. 2021 / 0189475, each of which is hereby incorporated by reference in its entirety.
[0089] As further shown, one or more spacers 110 may be positioned between the first substrate (e.g., slide 103) and the second substrate (e.g.. array slide 104 including spatially barcoded capture probes 106). The one or more spacers 110 may be configured to maintain a separation distance between the first substrate and the second substrate. While the one or more spacers 110 is shown as disposed on the second substrate, the spacer may additionally or alternatively be disposed on the first substrate.
[0090] In some embodiments, the one or more spacers 110 is configured to maintain a separation distance betw een first and second substrates that is betw een about 2 microns (pm) and about 1 mm (e g., betw een about 2 pm and about 800 pm, betw een about 2 pm and about 700 pm, between about 2 pm and about 600 pm, between about 2 pm and about 500 pm, between about 2 pm and about 400 pm. between about 2 pm and about 300 pm. between about 2 pm and about 200 pm, between about 2 pm and about 100 pm, betw een about 2 pm and about 25 pm, or betw een about 2 pm and about 10 pm), measured in a direction orthogonal to the surface of first substrate that supports the biological sample. In some instances, the separation distance is about 2. 3, 4, 5. 6, 7, 8, 9. 10. 11. 12. 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 pm. In some embodiments, the separation distance is less than 50 pm. In some embodiments, the separation distance is less than 25 pm. In some embodiments, the separation distance is less than 20 pm. The separation distance may include a distance of at least 2 pm.
[0091] FIG. IB shows a fully formed sandwich configuration 125 creating a chamber 150 formed from the one or more spacers 110, the first substrate (e.g., the slide 103), and the second substrate (e.g., the slide 104 including an array 106 having spatially barcoded capture probes) in accordance with some example implementations. In the example of FIG. IB, the liquid reagent (e.g., the permeabilization solution 105) fills the volume of the chamber 150 and may create a permeabilization buffer that allows analytes (e.g., mRNA transcripts and / or other molecules) or analyte derivatives (e.g., intermediate agents; e.g., ligation products) to diffuse from the biological sample 102 toward the capture probes of the second substrate (e.g., slide 104). In some aspects, flow of the permeabilization buffer may deflect transcripts and / or molecules from the biological sample 102 and may affect diffusive transfer of analytes or analyte derivatives (e.g., intermediate agents; e.g., ligation products) for spatial analysis. A partially or fully sealed chamber 150 resulting from the one or more spacers 110. the first substrate (e.g., slide 103), and the second substrate (e.g., slide 104) may reduce or prevent undesirable movement (e.g., convective movement) of transcripts and / or molecules during the diffusive transfer from the biological sample 102 to the capture probes.
[0092] The sandwiching process methods described above can be implemented using a variety of hardware components. For example, the sandwiching process methods can be implemented using a sample holder (also referred to herein as a support device, a sample handling apparatus, and an array alignment device). Further details on support devices, sample holders, sample handling apparatuses, or systems for implementing a sandwiching process are described in. e.g., U.S. Patent Application Pub. No. 2021 / 0189475 and PCT Publ. No. WO 2022 / 061152 A2, each of which is incorporated by reference in its entirety.
[0093] In some embodiments of a sample holder, the sample holder can include a first member including a first retaining mechanism configured to retain a first substrate comprising a biological sample. The first retaining mechanism can be configured to retain the first substrate disposed in a first plane. The sample holder can further include a second member including a second retaining mechanism configured to retain a second substrate disposed in a second plane. The sample holder can further include an alignment mechanism connected to one or both of the first member and the second member. The alignment mechanism can be configured to align the first and second members along the first plane and / or the second plane such that the sample contacts at least a portion of the reagent medium when the first and second members are aligned and within a threshold distance along an axis orthogonal to the second plane. The adjustment mechanism may be configured to move the second member along the axis orthogonal to the second plane and / or move the first member along an axis orthogonal to the first plane.
[0094] In some embodiments, the adjustment mechanism includes a linear actuator. In some embodiments, the linear actuator is configured to move the second member along an axis orthogonal to the plane of the first member and / or the second member. In some embodiments, the linear actuator is configured to move the first member along an axis orthogonal to the plane of the first member and / or the second member. In some embodiments, the linear actuator is configured to move the first member, the second member, or both the first member and the second member at a velocity of at least 0. 1 mm / sec. In some embodiments, the linear actuator is configured to move the first member, the second member, or both the first member and the second member with an amount of force of at least 0.1 lbs. FIG. 2A is a perspective view of an example sample handling apparatus 200 in a closed position in accordance with some example implementations. As shown, the sample handling apparatus 200 includes a first member 204, a second member 210, optionally an image capture device 220, a first substrate 206, optionally a hinge 215, and optionally a mirror 216. The hinge 215 may be configured to allow the first member 204 to be positioned in an open or closed configuration by opening and / or closing the first member 204 in a clamshell manner along the hinge 215.
[0095] FIG. 2B is a perspective view of the example sample handling apparatus 200 in an open position in accordance with some example implementations. As shown, the sample handling apparatus 200 includes one or more first retaining mechanisms 208 configured to retain one or more first substrates 206. In the example of FIG. 2B, the first member 204 is configured to retain two first substrates 206, however the first member 204 may be configured to retain more or fewer first substrates 206.
[0096] In some aspects, when the sample handling apparatus 200 is in an open position (e.g., in FIG. 2B), the first substrate 206 and / or the second substrate 212 may be loaded and positioned within the sample handling apparatus 200 such as within the first member 204 and the second member 210, respectively. As noted, the hinge 215 may allow the first member 204 to close over the second member 210 and form a sandwich configuration.
[0097] In some aspects, after the first member 204 closes over the second member 210, an adjustment mechanism of the sample handling apparatus 200 may actuate the first member 204 and / or the second member 210 to form the sandwich configuration for the permeabilization step (e.g., bringing the first substrate 206 and the second substrate 212 closer to each other and within a threshold distance for the sandwich configuration). The adjustment mechanism may be configured to control a speed, an angle, a force, or the like of the sandwich configuration.
[0098] In some embodiments, the biological sample (e.g., sample 102 from FIG. 1A) may be aligned within the first member 204 (e.g., via the first retaining mechanism 208) prior to closing the first member 204 such that a desired region of interest of the sample is aligned with the barcoded array of the second substrate (e.g., the slide 104 from FIG. 1A). e.g., when the first and second substrates are aligned in the sandwich configuration. Such alignment may be accomplished manually (e.g., by a user) or automatically (e.g., via an automated alignment mechanism). After or before alignment, spacers may be applied to the first substrate 206 and / or the second substrate 212 to maintain a minimum spacing between the first substrate 206 and the second substrate 212 during sandwiching. In some aspects, the permeabilization solution (e.g., permeabilization solution 305) may be applied to the first substrate 206 and / or the second substrate 212. The first member 204 may then close over the second member 210 and form the sandwich configuration. Analytes or analyte derivatives (e.g., intermediate agents; e.g., ligation products) may be captured by the capture probes of the array and may be processed for spatial analysis.
[0099] In some embodiments, during the permeabilization step, the image capture device 220 may capture images of the overlap area between the biological sample and the capture probes on the array 106. If more than one first substrates 206 and / or second substrates 212 are present within the sample handling apparatus 200, the image capture device 220 may be configured to capture one or more images of one or more overlap areas.
[0100] Provided herein are methods for delivering a fluid to a biological sample disposed on an area of a first substrate and an array disposed on a second substrate. FIGs. 3A-3C depict a side view and a top view of an exemplary angled closure workflow 300 for sandwiching a first substrate (e.g., slide 303) having a biological sample 302 and a second substrate (e.g., slide 304 having capture probes 306) in accordance with some exemplary implementations.
[0101] FIG. 3A depicts the first substrate (e.g.. slide 303 including a biological sample 302) angled over (superior to) the second substrate (e.g., slide 304). As shown, reagent medium (e.g., permeabilization solution) 305 is located on the spacer 310 toward the right-hand side of the side view in FIG. 3A. While FIG. 3A depicts the reagent medium on the right-hand side of side view, it should be understood that such depiction is not meant to be limiting as to the location of the reagent medium on the spacer.
[0102] FIG. 3B shows that as the first substrate lowers and / or as the second substrate rises, the dropped side of the first substrate (e.g., a side of the slide 303 angled toward the slide 304) may contact the reagent medium 305. The dropped side of the slide 303 may urge the reagent medium 305 toward the opposite direction (e.g., towards an opposite side of the spacer 310, towards an opposite side of the slide 303 relative to the dropped side). For example, in the side view of FIG. 3B the reagent medium 305 may be urged from right to left as the sandwich is formed.
[0103] In some embodiments, the first substrate and / or the second substrate are further moved to achieve an approximately parallel arrangement of the first substrate and the second substrate.
[0104] FIG. 3C depicts a full closure of the sandwich between the first substrate and the second substrate with the spacer 310 contacting both the first substrate and the second substrate and maintaining a separation distance and optionally the approximately parallel arrangement between the two substrates. As shown in the top view of FIG. 3C, the spacer 310 fully encloses and surrounds the biological sample 302 and the capture probes 306, and the spacer 310 form the sides of chamber 350 which holds a volume of the reagent medium 305
[0105] While FIG. 3C depicts the first substrate (e.g., the slide 303 including biological sample 302) angled over (superior to) the second substrate (e.g., slide 304) and the second substrate comprising the spacer 310. it should be understood that an exemplary angled closure workflow can include the second substrate angled over (superior to) the first substrate and the first substrate comprising the spacer 310.
[0106] It may be desirable that the reagent medium be free from air bubbles betw een the substrates to facilitate transfer of target analytes with spatial information. Additionally, air bubbles present between the substrates may obscure at least a portion of an image capture of a desired region of interest. Accordingly, it may be desirable to ensure or encourage suppression and / or elimination of air bubbles between the two substrates (e.g., slide 303 and slide 304) during a permeabilization step (e.g., step 104). In some aspects, it may be possible to reduce or eliminate bubble formation between the substrates using a variety of filling methods and / or closing methods. In some instances, the first substrate and the second substrate are arranged in an angled sandwich assembly as described herein. For example, during the sandwiching of the two substrates (e.g., the slide 303 and the slide 304). an angled closure workflow may be used to suppress or eliminate bubble formation.
[0107] FIG. 4A is a side view of the angled closure workflow 400 in accordance with some exemplary implementations. FIG. 4B is a top view of the angled closure workflow 400 in accordance with some exemplary implementations. As shown at step 405, reagent medium 401 is positioned to the side of the substrate 402.
[0108] At step 410, the dropped side of the angled substrate 406 contacts the reagent medium 401 first. The contact of the substrate 406 w ith the reagent medium 401 may form a linear or low' curvature flow front that fills the gap betw een the two substrates 406 and 402 uniformly with the slides closed.
[0109] At step 415, the substrate 406 is further lowered tow ard the substrate 402 (or the substrate 402 is raised up toward the substrate 406) and the dropped side of the substrate 406 may contact and urge the reagent medium toward the side opposite the dropped side, thereby creating a linear or low- curvature flow front that may prevent or reduce bubble trapping between the substrates. At step 420, the reagent medium 401 fills the gap between the substrate 406 and the substrate 402. The linear flow front of the liquid reagent may be formed by squeezing the reagent medium 401 volume along the contact side of the substrate 402 and / or the substrate 406. Additionally, capillary flow may also contribute to filling the gap area.
[0110] In some embodiments, the reagent medium (e.g., 105 in FIG. 1A) comprises a permeabilization agent. In some embodiments, following initial contact between the biological sample and a permeabilization agent, the permeabilization agent can be removed from contact with the biological sample (e.g., by opening the sample holder). Suitable agents for this purpose include, but are not limited to, organic solvents (e.g., acetone, ethanol, or methanol), cross-linking agents (e.g., paraformaldehyde), detergents (e.g., saponin. Triton X- 100™, Tween-20™. SDS), and enzymes (e.g., trypsin or other proteases (e.g.. proteinase K). In some embodiments, the detergent is an anionic detergent (e.g., SDS or N-lauroylsarcosine sodium salt solution).
[0111] In some embodiments, the reagent medium comprises a lysis reagent. Lysis solutions can include ionic surfactants such as, for example, sarkosyl and SDS. More generally, chemical lysis agents can include, without limitation, organic solvents, chelating agents, detergents, surfactants, and chaotropic agents. In some embodiments, the reagent medium comprises a protease. Exemplary proteases include, e.g., pepsin, trypsin, elastase, and proteinase K. In some embodiments, the reagent medium comprises a nuclease. In some embodiments, the nuclease comprises an RNase. In some embodiments, the RNase is selected from RNase A, RNase C, RNase H, and RNase I. In some embodiments, the reagent medium comprises one or more of SDS or a sodium salt thereof, proteinase K, pepsin, N- lauroylsarcosine, and RNase.
[0112] In some embodiments, the reagent medium comprises polyethylene glycol (PEG). In some embodiments, the PEG molecular weight is from about 2K to about 16K. In some embodiments, the PEG is about 2K, about 3K, about 4K, about 5K, about 6K, about 7K, about 8K, about 9K, about 10K, about UK, about 12K, about 13K, about 14K, about 15K, or about 16K. In some embodiments, the PEG is present at a concentration from about 2% to about 25%. from about 4% to about 23%, from about 6% to about 21%, or from about 8% to about 20% (v / v).
[0113] In certain embodiments, a dried permeabilization reagent is applied or formed as a layer on the first substrate, the second substrate, or both prior to contacting the biological sample with the array. For example, a permeabilization reagent can be deposited in solution on the first substrate or the second substrate or both and then dried. In some instances, the aligned portions of the biological sample and the array are in contact with the reagent medium for about 1 minute, about 5 minutes, about 10 minutes, about 12 minutes, about 15 minutes, about 18 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 36 minutes, about 45 minutes, or about an hour. In some instances, the aligned portions of the biological sample and the array are in contact with the reagent medium for about 1-60 minutes.
[0114] In some instances, the device is configured to control a temperature of the first and second substrates. In some embodiments, the temperature of the first and second members is lowered to a first temperature that is below room temperature.
[0115] There are at least two methods to associate a spatial barcode with one or more neighboring cells, such that the spatial barcode identifies the one or more cells, and / or contents of the one or more cells, as associated with a particular spatial location. One method is to promote analytes or analyte proxies (e.g., intermediate agents) out of a cell and towards a spatially -barcoded array (e.g., including spatially -barcoded capture probes). Another method is to cleave spatially-barcoded capture probes from an array and promote the spatially-barcoded capture probes towards and / or into or onto the biological sample.
[0116] In some cases, capture probes may be configured to prime, replicate, and consequently yield optionally barcoded extension products from a template (e.g., a DNA or RNA template, such as an analyte or an intermediate agent (e.g., a ligation product or an analyte capture agent), or a portion thereof), or derivatives thereof (see. e.g., Section (II)(b)(vii) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663 regarding extended capture probes, which is herein incorporated by reference). In some cases, capture probes may be configured to form ligation products with a template (e.g., a DNA or RNA template, such as an analyte or an intermediate agent, or portion thereof), thereby creating ligation products that serve as proxies for the template.
[0117] As used herein, an “extended capture probe” refers to a capture probe having additional nucleotides added to a terminus (e.g.. a 3’ or 5‘ end) of the capture probe, thereby extending the overall length of the capture probe. For example, an “extended 3‘ end” indicates additional nucleotides were added to the most 3' nucleotide of the capture probe to extend the length of the capture probe, for example, by polymerization reactions used to extend nucleic acid molecules including templated polymerization catalyzed by a polymerase (e.g., a DNA polymerase or a reverse transcriptase). In some embodiments, extending the capture probe includes adding to a 3’ end of a capture probe a nucleic acid sequence that is complementary to a nucleic acid sequence of an analyte or intermediate agent specifically bound to the capture domain of the capture probe. In some embodiments, the capture probe is extended using a reverse transcriptase. In some embodiments, the capture probe is extended using one or more DNA polymerases. In some embodiments, the extended capture probes include the sequence of the capture domain, the sequence of the spatial barcode of the capture probe, and the complementary sequence of the template used for extension of the capture probe.
[0118] In some embodiments, extended capture probes are amplified (e.g., in bulk solution or on the array) to yield quantities that are sufficient for downstream analysis, e.g., sequencing. In some embodiments, extended capture probes (e.g., DNA molecules) can act as templates for an amplification reaction (e.g., a polymerase chain reaction).
[0119] Additional variants of spatial analysis methods, including in some embodiments, an imaging step, are described in Section (II)(a) of PCT Publication No. W02020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference. Analysis of captured analytes (and / or intermediate agents or portions thereof), for example, including sample removal, extension of capture probes using the captured analyte as a template, sequencing (e.g., of a cleaved extended capture probe and / or a cDNA molecule complementary to an extended capture probe), sequencing on the array (e.g., using, for example, in situ hybridization or in situ ligation approaches), temporal analysis, and / or proximity capture, is described in Section (II)(g) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference. Some quality control measures are described in Section (II)(h) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663. which is herein incorporated by reference.
[0120] Spatial information can provide information of medical importance. For example, the methods described herein can allow for: identification of one or more biomarkers (e.g., diagnostic, prognostic, and / or for determination of efficacy of a treatment) of a disease or disorder; identification of a candidate drug target for treatment of a disease or disorder; identification (e.g.. diagnosis) of a subject as having a disease or disorder; identification of stage and / or prognosis of a disease or disorder in a subject; identification of a subject as having an increased likelihood of developing a disease or disorder; monitoring of progression of a disease or disorder in a subject; determination of efficacy of a treatment of a disease or disorder in a subject; identification of a patient subpopulation for which a treatment is effective for a disease or disorder; modification of a treatment of a subject with a disease or disorder; selection of a subject for participation in a clinical trial; and / or selection of a treatment for a subject with a disease or disorder. Exemplary methods for identifying spatial information of biological and / or medical importance can be found in U.S. Patent Application Publication Nos. 2021 / 0140982, 2021 / 0198741, and 2021 / 0199660, each of which is herein incorporated by reference in its entirety7.
[0121] Spatial information can provide information of biological importance. For example, the methods described herein can allow for: identification of transcriptome and / or proteome expression profiles (e g., in healthy and / or diseased tissue); identification of multiple analyte ty pes in close proximity7(e.g., nearest neighbor or proximity7based analysis); determination of up-regulated and / or down-regulated genes and / or proteins in diseased tissue; characterization of tumor microenvironments; characterization of tumor immune responses; characterization of cells types and their co-localization in healthy and diseased tissue; and identification of genetic variants within tissues (e.g., based on gene and / or protein expression profiles associated with specific disease or disorder biomarkers).
[0122] For spatial array-based methods, a substrate may function as a support for direct or indirect attachment of capture probes to features of the array. A “feature7’ is an entity that acts as a support or repository for various molecular entities used in spatial analysis. In some embodiments, some or all of the features in an array are functionalized for analyte capture. Exemplary substrates are described in Section (II)(c) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663. which is herein incorporated by reference. Exemplary features and geometric attributes of an array can be found in Sections (II)(d)(i), (II)(d)(iii), and (II)(d)(iv) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference.
[0123] Generally, analytes and / or intermediate agents (or portions thereof) can be captured when contacting a biological sample with a substrate including capture probes (e.g., a substrate with capture probes embedded, spotted, printed, fabricated on the substrate, or a substrate with features (e.g., beads or wells) comprising capture probes). As used herein, “contact.” “contacted,” and / or “contacting,” a biological sample with a substrate refers to any contact (e.g., direct or indirect) such that capture probes can interact (e.g., bind covalently or non-covalently (e.g., hybridize)) with analytes from the biological sample. Capture can be achieved actively (e.g., using electrophoresis) or passively (e.g., using diffusion). Analyte capture is further described in Section (II)(e) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference.
[0124] FIG. 5 is a schematic diagram showing an exemplary capture probe, as described herein. As shown, the capture probe 502 is optionally coupled to a feature 501 by a cleavage domain 503, such as a disulfide linker. The capture probe can include a functional sequence 504 that is useful for subsequent processing. The functional sequence 504 can include all or a part of sequencer specific flow cell attachment sequence (e.g., a P5 or P7 sequence), all or a part of a sequencing primer sequence, (e.g., a R1 primer binding site, a R2 primer binding site), or combinations thereof. The capture probe can also include a spatial barcode 505. The capture probe can also include a unique molecular identifier (UMI) sequence 506. While FIG. 5 shows the spatial barcode 505 as being located upstream (5’) of UMI sequence 506, it is to be understood that capture probes wherein UMI sequence 506 is located upstream (5’) of the spatial barcode 505 is also suitable for use in any of the methods described herein. The capture probe can also include a capture domain 507 to facilitate capture of a target analyte. The capture domain can have a sequence complementary to a sequence of a nucleic acid analyte. The capture domain can have a sequence complementary to a connected probe described herein. The capture domain can have a sequence complementary to an analyte capture sequence present in an analyte capture agent. The capture domain can have a sequence complementary to a splint oligonucleotide. A splint oligonucleotide, in addition to having a sequence complementary to a capture domain of a capture probe, can have a sequence complementary to a sequence of a nucleic acid analyte, a portion of a connected probe described herein, a capture handle sequence described herein, and / or a methylated adaptor described herein.
[0125] FIG. 6 is a schematic illustrating a cleavable capture probe, wherein the cleaved capture probe can enter into a non-permeabilized cell and bind to analytes within the cell. The capture probe 601 can contain a cleavage domain 602, a cell penetrating peptide 603, a reporter molecule 604, and a disulfide bond (-S-S-). 605 represents all other parts of a capture probe, for example, a spatial barcode and a capture domain.
[0126] FIG. 7 is a schematic diagram of an exemplary multiplexed spatially-barcoded feature. In FIG. 7, the feature 701 can be coupled to spatially-barcoded capture probes, wherein the spatially-barcoded probes of a particular feature can possess the same spatial barcode, but have different capture domains designed to associate the spatial barcode of the feature with more than one target analyte. For example, a feature may include four different types of spatially-barcoded capture probes, each type of spatially-barcoded capture probe possessing the spatial barcode 702. One type of capture probe associated with the feature can include the spatial barcode 702 in combination with a poly(T) capture domain 703. designed to capture mRNA target analytes. A second type of capture probe associated with the feature can include the spatial barcode 702 in combination with a random N-mer capture domain 704 for gDNA analysis. A third ty pe of capture probe associated with the feature can include the spatial barcode 702 in combination with a capture domain complementary to the analyte capture agent of interest 705. A fourth type of capture probe associated with the feature can include the spatial barcode 702 in combination with a capture probe that can specifically bind a nucleic acid molecule 706 that can function in a CRISPR assay (e.g., CRISPR / Cas9). While only four different capture probe-barcoded constructs are shown in FIG. 7, capture-probe barcoded constructs can be tailored for analyses of any given analyte associated with a nucleic acid and capable of binding with such a construct. For example, the schemes shown in FIG. 7 can also be used for concurrent analysis of other analytes disclosed herein, including, but not limited to: (a) mRNA, a lineage tracing construct, cell surface or intracellular proteins and / or metabolites, and gDNA; (b) mRNA, accessible chromatin (e.g., ATAC-seq, DNase-seq, and / or MNase-seq). cell surface or intracellular proteins and / or metabolites, and a perturbation agent (e.g., a CRISPR crRNA / sgRNA, TALEN, zinc finger nuclease, and / or antisense oligonucleotide as described herein); (c) mRNA, cell surface or intracellular proteins and / or metabolites, a barcoded labelling agent (e.g.. the MHC multimers described herein), and a V(D)J sequence of an immune cell receptor (e.g., T-cell receptor). In some embodiments, a perturbation agent can be a small molecule, an antibody, a drug, an aptamer, a miRNA, a physical environmental (e.g., temperature) change, or any other known perturbation agents.
[0127] The functional sequences can generally be selected for compatibility with any of a variety of different sequencing systems, e.g., Ion Torrent Proton or PGM, Illumina sequencing instruments, PacBio, Oxford Nanopore, etc., and the requirements thereof. In some embodiments, functional sequences can be selected for compatibility with noncommercialized sequencing systems. Examples of such sequencing systems and techniques, for which suitable functional sequences can be used, include (but are not limited to) Ion Torrent Proton or PGM sequencing, Illumina sequencing, PacBio SMRT sequencing, and Oxford Nanopore sequencing. Further, in some embodiments, functional sequences can be selected for compatibility' with other sequencing systems, including non-commercialized sequencing systems. In some embodiments, the spatial barcode 505 and functional sequence 504 are common to all of the probes attached to a given feature. In some embodiments, the UMI sequence 506 of a capture probe attached to a given feature is different from the UMI sequence of a different capture probe attached to the given feature.
[0128] FIG. 8 depicts an exemplary arrangement of barcoded features within an array. From left to right, FIG. 8 shows (left) a slide including six spatially-barcoded arrays, (center) an enlarged schematic of one of the six spatially-barcoded arrays, showing a grid of barcoded features in relation to a biological sample, and (right) an enlarged schematic of one section of an array, showing the specific identification of multiple features within the array (e.g., labelled as ID578, ID579, ID580, etc.).
[0129] In some embodiments, more than one analyte type (e.g.. nucleic acids and proteins) from a biological sample can be detected (e.g., simultaneously or sequentially) using any appropriate multiplexing technique, such as those described in Section (IV) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663. which is herein incorporated by reference.
[0130] In some cases, spatial analysis can be performed by attaching and / or introducing a molecule (e.g., a peptide, a lipid, or a nucleic acid molecule) having a barcode (e.g., a spatial barcode) to a biological sample (e.g., to a cell in a biological sample). In some embodiments, a plurality of molecules (e.g., a plurality of nucleic acid molecules) having a plurality of barcodes (e.g., a plurality of spatial barcodes) are introduced to a biological sample (e.g., to a plurality of cells in a biological sample) for use in spatial analysis. In some embodiments, after attaching and / or introducing a molecule having a barcode to a biological sample, the biological sample can be physically separated (e.g., dissociated) into single cells or cell groups for analysis. Some such methods of spatial analysis are described in Section (III) of PCT Publication No. W02020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference.
[0131] In some cases, spatial analysis can be performed by detecting multiple oligonucleotides that hybridize to an analyte. In some instances, for example, spatial analysis can be performed using RNA-templated ligation (RTL). Methods of RTL have been described previously. See, e.g., Credle et al., Nucleic Acids Res. 2017 Aug 21; 45(14):el28, which is herein incorporated by reference in its entirety. Typically, RTL includes hybridization of two oligonucleotides to adjacent sequences on an analyte (e.g., an RNA molecule, such as an mRNA molecule). In some instances, the oligonucleotides are DNA molecules. In some instances, one of the oligonucleotides includes at least two ribonucleic acid bases at the 3‘ end and / or the other oligonucleotide includes a phosphory lated nucleotide at the 5' end. In some instances, one of the two oligonucleotides includes a capture probe binding domain (e.g., a poly(A) sequence or anon-homopolymeric sequence). After hybridization to the analyte, a ligase (e.g., a T4 RNA ligase (Rnl2), a PBCV-1 DNA Ligase or Chlorella virus DNA Ligase, a single-stranded DNA ligase, or a T4 DNA ligase) ligates the two oligonucleotides together, creating a ligation product. In some instances, the two oligonucleotides hybridize to sequences that are not adjacent to one another. For example, hybridization of the two oligonucleotides creates a gap between the hybridized oligonucleotides. In some instances, a polymerase (e.g., a DNA polymerase) can extend one of the oligonucleotides prior to ligation. After ligation, the ligation product is released from the analyte. In some instances, the ligation product is released using an endonuclease (e.g.. RNase H). In some instances, the ligation product is removed using heat. In some instances, the ligation product is removed using KOH. The released ligation product can then be captured by capture probes (e.g.. instead of direct capture of an analyte) on an array, optionally amplified, and sequenced, thus determining the location, and optionally, the abundance of the analyte in the biological sample.
[0132] In some instances, one or both of the oligonucleotides may hybridize to genomic DNA (gDNA), which can lead to false positive sequencing data from ligation events on gDNA (off target) in addition to the desired (on target) ligation events on target nucleic acids (e.g.. mRNA). Thus, in some embodiments, the disclosed methods can include contacting the biological sample with a deoxyribonuclease (DNase). The DNase can be an endonuclease or exonuclease. In some embodiments, the DNase digests single-stranded and / or doublestranded DNA. Suitable DNases include, without limitation, a DNase I and a DNase II. Use of a DNase as described can mitigate false positive sequencing data from off target gDNA ligation events.
[0133] A non-limiting example of templated ligation methods disclosed herein is depicted in FIG. 9A. After a biological sample is contacted with a substrate including a plurality of capture probes and contacted with (a) a first probe 901 having a target-hybridization sequence 903 and a primer sequence 902 and (b) a second probe 904 having a targethybridization sequence 905 and a capture domain (e.g., a poly(A) sequence) 906, the first probe 901 and the second probe 904 hybridize 910 to an analyte 907. A ligase 921 ligates 920 the first probe 901 to the second probe 904, thereby generating a ligation product 922. The ligation product 922 is then released 930 from the analyte 931 by digesting the analyte 907 using an endoribonuclease 932. The sample is permeabilized 940 and the ligation product 941 is able to hybridize to a capture probe on the substrate. Methods and compositions for spatial detection using templated ligation have been described in PCT Publication. No. WO 2021 / 133849 Al, U.S. Pat. Nos. 1 1,332,790 and 11,505,828, each of which is incorporated by reference in its entirety.
[0134] In some embodiments, as shown in FIG. 9B, the ligation product 9001 includes a capture probe capture domain 9002, which can bind to a capture probe 9003 (e.g., a capture probe immobilized, directly or indirectly, on a substrate 9004). In some embodiments, methods provided herein include contacting 9005 a biological sample with a substrate 9004, wherein the capture probe 9003 is affixed to the substrate (e.g., immobilized to the substrate, directly or indirectly). In some embodiments, the capture probe capture domain 9002 of the ligated product 9001 specifically binds to the capture domain 9006. The capture probe can also include a unique molecular identifier (UMI) 9007, a spatial barcode 9008, a functional sequence 9009, and a cleavage domain 9010.
[0135] In some embodiments, methods provided herein include permeabilization of the biological sample such that the capture probe can more easily capture the ligation products (i. e. , compared to no permeabilization). In some embodiments, polymerization (e.g.. reverse transcription (RT)) reagents can be added to permeabilized biological samples. Incubation with the polymerization reagents can be used to extend the capture probes 9011 to produce spatially -barcoded full-length cDNA 9012 and 9013 from the captured ligation products (e.g., ligation products). The ligation products can be extended using the capture probe as a template to include a complement of the capture probe, thereby generating extended ligation products.
[0136] In some embodiments, the extended ligation products can be denatured 9014, released from the capture probe, and transferred (e.g., to a clean tube) for amplification and / or library construction. The spatially-barcoded ligation products can be amplified 9015 via PCR prior to library construction. P5 9016, i5 9017, i7 9018, and P7 9019 sequences can be used as sample indexes. The amplicons can then be sequenced using paired-end sequencing using TruSeq Read 1 and TruSeq Read 2 as sequencing primer sites.
[0137] In some embodiments, detection of one or more analytes (e.g., protein analytes) can be performed using one or more analyte capture agents. As used herein, an “analyte capture agent” refers to an agent that interacts with an analyte (e.g., an analyte in a biological sample) and with a capture probe (e.g., a capture probe attached to a substrate or a feature) to identify the analyte. In some embodiments, the analyte capture agent includes: (i) an analyte binding moiety (e.g., that binds to an analyte), for example, an antibody or antigen-binding fragment thereof; (ii) analyte binding moiety barcode; and (iii) an analyte capture sequence. As used herein, the term "‘analyte binding moiety barcode’7refers to a barcode that is associated with or otherwise identifies the analyte binding moiety. As used herein, the term ‘‘analyte capture sequence” refers to a region or moiety configured to hybridize to, bind to, couple to, or otherwise interact with a capture domain of a capture probe. In some cases, an analyte binding moiety barcode (or portion thereof) may be able to be removed (e.g.. cleaved) from the analyte capture agent. Additional description of analyte capture agents can be found in Section (II)(b)(ix) of PCT Publication No. WO2020 / 176788 and / or Section (II)(b)(viii) U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference.
[0138] FIG. 10 is a schematic diagram of an exemplary analyte capture agent 1002 comprised of an analyte binding moiety 1004 and an analyte- binding moiety barcode domain 1008. The exemplary analyte binding moiety 1004 is capable of binding to an analyte 1006 and the analyte capture agent 1002 is capable of interacting with a spatially -barcoded capture probe. The analyte binding moiety 1004 can bind to the analyte 1006 with high affinity and / or with high specificity. The analyte capture agent 1002 can include: (i) an analyte binding moiety barcode domain 1008. which serves to identify the analyte binding moiety, and (ii) an analyte capture sequence, which can hybridize to at least a portion or an entirety of a capture domain of a capture probe. The analyte binding moiety 1004 can include a polypeptide and / or an aptamer. The analyte binding moiety 1004 can include an antibody or antibody fragment (e.g., an antigen-binding fragment).
[0139] FIG. 11 is a schematic diagram depicting an exemplary interaction between a feature-immobilized capture probe 1124 and an analyte capture agent 1126. The feature- immobilized capture probe 1124 can include a spatial barcode 1108 as well as functional sequence 1106 and a UMI 1110. as described elsewhere herein. The capture probe can be affixed 1104 to a feature such as a bead 1102. The capture probe 1124 can also include a capture domain 1112 that is capable of binding to an analyte capture agent 1126. The analyte binding moiety barcode domain of the analyte capture agent 1126 can include functional sequence 1118, analyte binding moiety barcode 1116. and an analyte capture sequence 1114 that is capable of binding (e.g., hybridizing) to the capture domain 1112 of the capture probe 1124. The analyte capture agent 1126 can also include a linker 1120 that allows the analyte binding moiety barcode domain (e.g., including the functional sequence 1118, analyte binding moiety barcode 1116, and analyte capture sequence 1114) to couple to the analyte binding moiety 1122. In some embodiments, the linker 1120 is a cleavable linker. In some embodiments, the cleavable linker is a photo-cleavable linker, a UV-cleavable linker. chemical-cleavable, thermal-cleavable, or an enzyme cleavable linker. In some instances, the cleavable linker is a disulfide linker. A disulfide linker can be cleaved by use of a reducing agent, such as dithiothreitol (DTT), beta-mercaptoethanol (BME), or Tris (2-carboxyethyl) phosphine (TCEP).
[0140] During analysis of spatial information, sequence information for a spatial barcode associated with an analyte is obtained, and the sequence information can be used to provide information about the spatial distribution of the analyte in the biological sample. Various methods can be used to obtain the spatial information. In some embodiments, specific capture probes and the captured analytes are associated with specific locations in an array of features on a substrate. For example, specific spatial barcodes can be associated with specific array locations prior to array fabrication, and the sequences of the spatial barcodes can be stored (e.g., in a database) along with specific array location information, so that each spatial barcode uniquely maps to a particular array location.
[0141] Alternatively, specific spatial barcodes can be deposited at predetermined locations in an array of features during fabrication such that at each location, only one type of spatial barcode is present so that each spatial barcode is uniquely associated with a single feature of the array. Where necessary, the arrays can be decoded using any of the methods described herein so that spatial barcodes are uniquely associated with array feature locations, and this mapping can be stored as described above.
[0142] When sequence information is obtained for capture probes and / or analytes during analysis of spatial information, the locations of the capture probes and / or analytes can be determined by referring to the stored information that uniquely associates each spatial barcode with an array feature location. In this manner, specific capture probes and captured analytes are associated with specific locations in the array of features. Each array feature location represents a position relative to a coordinate reference point (e.g., an array location or a fiducial marker) of the array. Accordingly, each feature location has an “address” or location in the coordinate space of the array.
[0143] Some exemplary spatial analysis workflows are described in the Exemplary- Embodiments section of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663, which is herein incorporated by reference. See, for example, the Exemplary embodiment starting with “In some non-limiting examples of the workflows described herein, the sample can be immersed. . . ” of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663. which is herein incorporated by reference. See also, e.g., the Visium Spatial Gene Expression Reagent Kits User Guide (e.g., Rev F, dated January 2022) and / or the Visium Spatial Gene Expression Reagent Kits - Tissue Optimization User Guide (e.g., Rev E, dated February 2022), each of which is herein incorporated by reference in its entirety.
[0144] In some embodiments, spatial analysis can be performed using dedicated hardware and / or software, such as any of the systems described in Sections (II)(e)(ii) and / or (V) of PCT Publication No. WO2020 / 176788 and / or U.S. Patent Application Publication No. 2020 / 0277663. or any of one or more of the devices or methods described in Sections Control Slide for Imaging, Methods of Using Control Slides and Substrates for, Systems of Using Control Slides and Substrates for Imaging, and / or Sample and Array Alignment Devices and Methods, Informational labels of PCT Publication No. W02020 / 123320, which is herein incorporated by reference.
[0145] Suitable systems for performing spatial analysis can include components such as a chamber (e.g., a flow cell or a sealable, fluid-tight chamber) for containing a biological sample. The biological sample can be mounted, for example, in a biological sample holder. One or more fluid chambers can be connected to the chamber and / or the sample holder via fluid conduits, and fluids can be delivered into the chamber and / or sample holder via fluidic pumps, vacuum sources, or other devices coupled to the fluid conduits that create a pressure gradient to drive fluid flow. One or more valves can also be connected to fluid conduits to regulate the flow of reagents from reservoirs to the chamber and / or sample holder.
[0146] The systems can optionally include a control unit that includes one or more electronic processors, an input interface, an output interface (such as a display), and a storage unit (e.g., a solid state storage medium such as, but not limited to, a magnetic, optical, or other solid state, persistent, writeable, and / or re-writeable storage medium). The control unit can optionally be connected to one or more remote devices via a network. The control unit (and components thereof) can generally perform any of the steps and functions described herein. Where the system is connected to a remote device, the remote device (or devices) can perform any of the steps or features described herein. The systems can optionally include one or more detectors (e.g., CCD, CMOS) used to capture images. The systems can also optionally include one or more light sources (e.g.. LED-based, diode-based, lasers) for illuminating a sample, a substrate with features, analytes from a biological sample captured on a substrate, and various control and calibration media.
[0147] The systems can optionally include software instructions encoded and / or implemented in one or more of tangible storage media and hardware components such as application specific integrated circuits. The software instructions, when executed by a control unit (and in particular, an electronic processor) or an integrated circuit, can cause the control unit, integrated circuit, or other component executing the software instructions to perform any of the method steps or functions described herein.
[0148] In some cases, the systems described herein can detect (e.g., register an image) the biological sample on the array. Exemplar}7methods to detect the biological sample on an array are described in PCT Publication No. W02021 / 102003 and / or U.S. Patent Application Publication No. 2021 / 0150707, each of which is incorporated herein by reference in its entirety.
[0149] Prior to transferring analytes from the biological sample to the array of features on the substrate, the biological sample can be aligned with the array. Alignment of a biological sample and an array of features including capture probes can facilitate spatial analysis, which can be used to detect differences in analyte presence and / or level within different positions in the biological sample, for example, to generate a three-dimensional map of the analyte presence and / or level. Exemplary methods to generate a two-dimensional and / or three- dimensional map of the analyte presence and / or level are described in PCT Publication No. W02020 / 053655 and spatial analysis methods are generally described in PCT Publication No. W02021 / 102039 and / or U.S. Patent Application Publication No. 2021 / 0155982, each of which is incorporated herein by reference in its entirety7.
[0150] In some cases, a map of analyte presence and / or level can be aligned to an image of a biological sample using one or more fiducial markers, e.g., objects placed in the field of view of an imaging system which appear in the image produced, as described in the Substrate Attributes Section, Control Slide for Imaging Section of PCT Publication Nos. W02020 / 123320, WO 2021 / 102005, and / or U.S. Patent Application Publication No. 2021 / 0158522. each of which is incorporated herein by reference in its entirety. Fiducial markers can be used as a point of reference or measurement scale for alignment (e.g., to align a sample and an array, to align two substrates, to determine a location of a sample or arrays on a substrate relative to a fiducial marker) and / or for quantitative measurements of sizes and / or distances.
[0151] B. Methods of reducing transcript mislocalization of a target analyte
[0152] Spatial transcriptomics would benefit from methods that could minimize target analyte mislocalization. For example, analytes (e.g., target sequences) typically migrate vertically to the substrate where they are captured by the capture domain of a capture probe. However, analyte mislocalization, including transcript mislocalization (e.g., diffusion, flow, convection based), can result in incorrect registration of spatial information, which leads to incorrect detection of spatial gene expression and cell type identification in spatial data. As such, reducing transcript mislocalization would have a positive impact on the quality of spatial data.
[0153] Accordingly, in some embodiments, the methods herein employ a gel / polymer based system that provides a physical constraint that limits movement of molecules, while methods to capture analytes, such as transcripts or probes, are initiated (e.g., methods including permeabilization of the biological sample). For example, the tissue is digested, however the gel / polymer remains intact to regulate flow of molecules (e.g., transcripts or probes), thereby minimizing transcript mislocalization. In some embodiments, the analyte can be an intermediate agent (e.g., a ligation product, such as any described herein), which can optionally serve as a proxy for a target analyte.
[0154] Provided herein are methods for identifying a location of an analyte in a biological sample, the method including (a) contacting the biological sample with a substrate, wherein the substrate comprises a plurality of capture probes, and wherein at least one capture probe of the plurality7of capture probes comprises a capture domain and a spatial barcode; (b) embedding the biological sample in a porous hydrogel or coating the biological sample with the porous hydrogel; (c) permeabilizing the biological sample to release the analyte and allow the analyte, or a proxy thereof, in the biological sample to migrate to and interact with the at least one capture probe of the plurality' of capture probes; (d) hybridizing the analyte, or the proxy thereof, to a capture domain of the at least one capture probe; and (e) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte, or the proxy thereof, or a complement of any of these from the biological sample, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample.
[0155] As used herein, a “capture probe” refers to any molecule capable of capturing (directly or indirectly) and / or labelling an analyte (e.g., an analyte of interest) in a biological sample. In some embodiments, the capture probe is a nucleic acid or a polypeptide. In some embodiments, the capture probe includes a barcode (e.g., a spatial barcode) and a capture domain. In some embodiments, a capture probe can include one or more of a unique molecular identifier (UMI), a cleavage domain, and / or a functional sequence (e.g., a primerbinding site, a sequencing domain such as for next-generation sequencing (NGS)). In some embodiments, a capture probe includes a capture domain and a spatial barcode. In some embodiments, the capture domain interacts with the analyte, or the proxy thereof. The capture domain can be configured to capture any analyte of interest. In some embodiments, the analyte of interest is an intermediate agent. In some embodiments, the intermediate agent is a ligation product, for example, which is a proxy for a target analyte. In some embodiments, the analyte of interest is a target sequence. In some embodiments, the target sequence can include a synthetic or natural sequence. In some embodiments, the target sequence is a DNA, an RNA, or a mRNA. In some embodiments, the spatial barcode comprises a sequence unique to the location on the substrate that can be used to identify the location of the target analyte on the substrate.
[0156] In some embodiments, the methods described herein comprises one or more of the following: (i) contacting the substrate with a silane solution (e.g., a bind-silane solution); (ii) contacting the biological sample with an acrylic ester (e.g., Acrylic acid N- hydroxysuccinimide (NHS) ester); (iii) destaining the biological sample, wherein the biological sample was previously stained (e.g., using an H&E staining method); and (iv) washing the biological sample with PBST (phosphate buffered saline with Tween20).
[0157] Also provided herein are methods of reducing mislocalization of an analyte in a biological sample, the method comprising: (a) providing the biological sample on a substrate, wherein the substrate comprises a plurality of capture probes, and wherein at least one capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode; (b) contacting the biological sample with at least one monomer; (c) polymerizing the at least one monomer in the presence of at least one catalyst to form a porous hydrogel, thereby embedding the biological sample in the porous hydrogel or coating the biological sample with the porous hydrogel; and (d) permeabilizing the embedded biological sample or the coated biological sample to allow the analyte, or a proxy thereof, in the biological sample to migrate to and interact with the at least one capture probe of the plurality of capture probes, thereby reducing mislocalization of the analyte in the biological sample.
[0158] In some embodiments, the methods described herein can further comprise: (e) extending the at least one capture probe using the analyte as a template; and (f) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte from the biological sample, or a complement thereof, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample.
[0159] In some embodiments, the methods described herein can further comprise: (e) hybridizing a ligation product to the capture domain of the at least one capture probe, wherein the ligation product comprises a sequence that is substantially complementary' to a sequence of an analyte in the biological sample; and (f) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the ligation product, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample.
[0160] Also described herein are methods for identifying a location of an analyte in a biological sample, the method comprising: (a) contacting the biological sample with a first substrate; (b) forming a porous hydrogel within or surrounding the biological sample, thereby embedding the biological sample in the porous hydrogel or coating the biological sample with the porous hydrogel; (c) aligning the first substrate with a second substrate comprising an array, such that at least a portion of the biological sample is aligned with at least a portion of the array, wherein the array comprises a plurality of capture probes, wherein at least one capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode; (d) when the biological sample is aligned with at least a portion of the array, capturing the analyte, or a proxy thereof, using the at least one capture probe; and (e) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte, or a proxy thereof, from the biological sample, or a complement thereof, and using the determined sequences of (i) and (ii) to identify' the location of the analyte in the biological sample.
[0161] In some embodiments, capturing further comprises migrating the analyte, or the proxy thereof, from the biological sample to the array. In some embodiments, migration comprises migration in a vertical direction between the biological sample and the array, which can be facilitated by permeabilizing the tissue embedded or covered (or coated) by the hydrogel.
[0162] In some embodiments, aligning comprises: mounting the first substrate on a first member of a support device, the first member configured to retain the first substrate; mounting the second substrate on a second member of the support device; applying a reagent medium to the first substrate and / or the second substrate; and operating an alignment mechanism of the support device to move the first member and / or the second member such that at least a portion of the biological sample is aligned with at least a portion of the array, and such that the portion of the biological sample and the portion of the array contact the reagent medium.
[0163] In some embodiments, capturing comprises contacting the biological sample with a reagent medium comprising a permeabilization agent, thereby permeabilizing the biological sample to allow the analyte, or the proxy thereof, in the biological sample to interact with the capture probes on the array. C. Hydrogels
[0164] In some embodiments, the methods described herein can include forming a porous hydrogel that permeates or surrounds the biological sample. As used herein, a "hydrogel" can refer to a gel in which the swelling agent in water. In turn, the gel may be composed of a polymeric network. In some embodiments, the hydrogel can include a cross-linked three- dimensional (3D) network of hydrophilic polymer chains. Hydrogels can be synthesized from chain polymerization of monomers (e.g., multifunctional macromolecular monomers), wherein the hydrogel can contain a high volume of water while being structurally stable. Such stability can be provided by chemical or physical interactions (including covalent or non-covalent interactions), such as by cross-linking of polymer chains or by induced gelation of monomers by an external stimulus (e.g., pH, ionic concentration, temperature, and the like). In some embodiments, hydrogels are synthesized using a monomer, an optional crosslinking chemical, and specific reaction conditions. In some examples, a monomer can include a reactive group that allows for polymerization. In other examples, a monomer can be used with another co-monomer and / or a cross-linking chemical during polymerization. For example, based on the methods of synthesis, hydrogels may be classified as a copolymer, a semi-interpenetrating network (semi-IPN) homopolymer, or an interpenetrating network (IPN). In some embodiments, homopolymers have only one type of monomer in their structure and, based on the monomer's nature and the polymerization process, they may have a cross-linked structure. In some embodiments, copolymeric hydrogels can have a plurality of monomers, and at least one monomer in copolymeric hydrogels is hydrophilic.
[0165] Hydrogels can include other solvents that are not water, such as in an organogel in which the swelling agent is an organic solvent (e.g., an ether, an alkane, an alcohol, or mixtures thereof). Hydrogels may be present in other forms, such as a xerogel or an aerogel.
[0166] In some embodiments, a hydrogel can include hydrogel subunits. A ‘"hydrogel subunit” can be a hydrophilic monomer, a molecular precursor, or a polymer that can be polymerized (e.g., cross-linked) to form a hydrogel (e.g., a 3D hydrogel network). The hydrogel subunits can include any convenient hydrogel subunits, such as, but not limited to, acrylamide and derivatives thereof (e.g.. alkyl acrylamide), bis-acrylamide and derivatives thereof (e.g.. AtyV-alkylene bis-acrylamide, such as A.A-methylenebisacrylamide). acrylate and derivatives thereof (e g., sodium acrylate or alkyl acrylate), methacrylate and derivatives thereof (e.g., alkyl methacry late or methacryloyl), bis-acrylate and derivatives thereof, polyacrylamide and derivatives thereof, poly(ethylene glycol) and derivatives thereof (e.g., PEG-acrylate (PEG-DA), PEG methacrylate (PEGMA), PEG-RGD), gelatin-methacryloyl (GelMA), methacrylated hyaluronic acid (MeHA), polyaliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohols, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxyethyl acrylate), and poly(hydroxyethyl methacrylate), collagen, hyaluronic acid, chitosan, dextran, agarose, gelatin, heparin, fibrin, alginate, glutaraldehyde, protein polymers, methylcellulose, and the like, or combinations thereof. For any compounds described herein (e.g., monomers, catalysts, etc.), salt forms may be employed (e.g., sodium salts, hydrochloride salts, and the like), and ionic forms may be employed (e.g., anionic or cationic forms).
[0167] Polymerization of the hydrogel
[0168] In some embodiments, forming a hydrogel can include contacting the biological sample with at least one monomer and / or at least one catalyst. In some embodiments, the biological sample is contacted with the at least one monomer prior to providing the at least one catalyst. In some embodiments, the biological sample is contacted with the at least one monomer for a period from about 5 minutes to about 1 hour (e.g., about 5 minutes to about 50 minutes, about 5 minutes to about 40 minutes, about 5 minutes to about 30 minutes, about 5 minutes to about 20 minutes, about 5 minutes to about 15 minutes, about 5 minutes to about 10 minutes, about 10 minutes to about 1 hour, about 10 minutes to about 50 minutes, about 10 minutes to about 40 minutes, about 10 minutes to about 30 minutes, about 10 minutes to about 20 minutes, about 10 minutes to about 15 minutes, about 15 minutes to about 1 hour, about 15 minutes to about 50 minutes, about 15 minutes to about 40 minutes, about 15 minutes to about 30 minutes, about 15 minutes to about 20 minutes, about 20 minutes to about 1 hour, about 20 minutes to about 50 minutes, about 20 minutes to about 40 minutes, about 20 minutes to about 30 minutes, about 30 minutes to about 1 hour, about 30 minutes to about 50 minutes, about 30 minutes to about 40 minutes, about 40 minutes to about 1 hour, about 40 minutes to about 50 minutes, or about 50 minutes to about 1 hour)prior to providing the at least one catalyst. In some embodiments, forming can include contacting the biological sample with the at least one catalyst for a period from about 5 seconds to overnight (about 16hrs) (e.g., about 5 seconds to about 14 hours, about 5 seconds to about 12 hours, about 5 seconds to about 10 hours, about 5 seconds to about 8 hours, about 5 seconds to about 6 hours, about 5 seconds to about 4 hours, about 5 seconds to about 2 hours, about 5 seconds to about 1 hour, about 5 seconds to about 50 minutes, about 5 seconds to about 40 minutes, about 5 seconds to about 30 minutes, about 5 seconds to about 20 minutes, about 5 seconds to about 10 minutes, about 5 seconds to about 5 minutes, about 5 seconds to about 1 minute, about 5 seconds to about 30 seconds, about 30 seconds to about 16 hours, about 30 seconds to about 14 hours, about 30 seconds to about 12 hours, about 30 seconds to about 10 hours, about 30 seconds to about 8 hours, about 30 seconds to about 6 hours, about 30 seconds to about 4 hours, about 30 seconds to about 2 hours, about 30 seconds to about 1 hour, about 30 seconds to about 50 minutes, about 30 seconds to about 40 minutes, about 30 seconds to about 30 minutes, about 30 seconds to about 20 minutes, about 30 seconds to about 10 minutes, about 30 seconds to about 5 minutes, about 30 seconds to about 1 minute, about 1 minute to about 16 hours, about 1 minute to about 14 hours, about 1 minute to about 12 hours, about 1 minute to about 10 hours, about 1 minute to about 8 hours, about 1 minute to about 6 hours, about 1 minute to about 4 hours, about 1 minute to about 2 hours, about 1 minute to about 1 hour, about 1 minute to about 50 minutes, about 1 minute to about 40 minutes, about 1 minute to about 30 minutes, about 1 minute to about 20 minutes, about 1 minute to about 10 minutes, about 1 minute to about 5 minutes, about 5 minutes to about 16 hours, about 5 minutes to about 14 hours, about 5 minutes to about 12 hours, about 5 minutes to about 10 hours, about 5 minutes to about 8 hours, about 5 minutes to about 6 hours, about 5 minutes to about 4 hours, about 5 minutes to about 2 hours, about 5 minutes to about 1 hour, about 5 minutes to about 50 minutes, about 5 minutes to about 40 minutes, about 5 minutes to about 30 minutes, about 5 minutes to about 20 minutes, about 5 minutes to about 10 minutes, about 10 minutes to about 16 hours, about 10 minutes to about 14 hours, about 10 minutes to about 12 hours, about 10 minutes to about 10 hours, about 10 minutes to about 8 hours, about 10 minutes to about 6 hours, about 10 minutes to about 4 hours, about 10 minutes to about 2 hours, about 10 minutes to about 1 hour, about 10 minutes to about 50 minutes, about 10 minutes to about 40 minutes, about 10 minutes to about 30 minutes, about 10 minutes to about 20 minutes, about 20 minutes to about 16 hours, about 20 minutes to about 14 hours, about 20 minutes to about 12 hours, about 20 minutes to about 10 hours, about 20 minutes to about 8 hours, about 20 minutes to about 6 hours, about 20 minutes to about 4 hours, about 20 minutes to about 2 hours, about 20 minutes to about 1 hour, about 20 minutes to about 50 minutes, about 20 minutes to about 40 minutes, about 20 minutes to about 30 minutes, about 30 minutes to about 16 hours, about 30 minutes to about 14 hours, about 30 minutes to about 12 hours, about 30 minutes to about 10 hours, about 30 minutes to about 8 hours, about 30 minutes to about 6 hours, about 30 minutes to about 4 hours, about 30 minutes to about 2 hours, about 30 minutes to about 1 hour, about 30 minutes to about 50 minutes, about 30 minutes to about 40 minutes, about 40 minutes to about 16 hours, about 40 minutes to about 14 hours, about 40 minutes to about 12 hours, about 40 minutes to about 10 hours, about 40 minutes to about 8 hours, about 40 minutes to about 6 hours, about 40 minutes to about 4 hours, about 40 minutes to about 2 hours, about 40 minutes to about 1 hour, about 40 minutes to about 50 minutes, about 50 minutes to about 16 hours, about 50 minutes to about 14 hours, about 50 minutes to about 12 hours, about 50 minutes to about 10 hours, about 50 minutes to about 8 hours, about 50 minutes to about 6 hours, about 50 minutes to about 4 hours, about 50 minutes to about 2 hours, about 50 minutes to about 1 hour, about 1 hour to about 16 hours, about 1 hour to about 14 hours, about 1 hour to about 12 hours, about 1 hour to about 10 hours, about 1 hour to about 8 hours, about 1 hour to about 6 hours, about 1 hour to about 4 hours, about 1 hour to about 2 hours, about 2 hours to about 16 hours, about 2 hours to about 14 hours, about 2 hours to about 12 hours, about 2 hours to about 10 hours, about 2 hours to about 8 hours, about 2 hours to about 6 hours, about 2 hours to about 4 hours, about 4 hours to about 16 hours, about 4 hours to about 14 hours, about 4 hours to about 12 hours, about 4 hours to about 10 hours, about 4 hours to about 8 hours, about 4 hours to about 6 hours, about 6 hours to about 16 hours, about 6 hours to about 14 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours, about 6 hours to about 8 hours, about 8 hours to about 16 hours, about 8 hours to about 14 hours, about 8 hours to about 12 hours, about 8 hours to about 10 hours, about 10 hours to about 16 hours, about 10 hours to about 14 hours, about 10 hours to about 12 hours, about 12 hours to about 16 hours, about 12 hours to about 14 hours, or about 14 hours to about 16 hours).
[0169] In some embodiments, the biological sample is contacted with the at least one monomer and the at least one catalyst simultaneously. In some embodiments, the biological sample is contacted with the at least one monomer and the at least one catalyst simultaneously for a period from about 5 seconds to overnight (about 16hrs) (e.g., about 5 seconds to about 14 hours, about 5 seconds to about 12 hours, about 5 seconds to about 10 hours, about 5 seconds to about 8 hours, about 5 seconds to about 6 hours, about 5 seconds to about 4 hours, about 5 seconds to about 2 hours, about 5 seconds to about 1 hour, about 5 seconds to about 50 minutes, about 5 seconds to about 40 minutes, about 5 seconds to about 30 minutes, about 5 seconds to about 20 minutes, about 5 seconds to about 10 minutes, about 5 seconds to about 5 minutes, about 5 seconds to about 1 minute, about 5 seconds to about 30 seconds, about 30 seconds to about 16 hours, about 30 seconds to about 14 hours, about 30 seconds to about 12 hours, about 30 seconds to about 10 hours, about 30 seconds to about 8 hours, about 30 seconds to about 6 hours, about 30 seconds to about 4 hours, about 30 seconds to about 2 hours, about 30 seconds to about 1 hour, about 30 seconds to about 50 minutes, about 30 seconds to about 40 minutes, about 30 seconds to about 30 minutes, about 30 seconds to about 20 minutes, about 30 seconds to about 10 minutes, about 30 seconds to about 5 minutes, about 30 seconds to about 1 minute, about 1 minute to about 16 hours, about 1 minute to about 14 hours, about 1 minute to about 12 hours, about 1 minute to about 10 hours, about 1 minute to about 8 hours, about 1 minute to about 6 hours, about 1 minute to about 4 hours, about 1 minute to about 2 hours, about 1 minute to about 1 hour, about 1 minute to about 50 minutes, about 1 minute to about 40 minutes, about 1 minute to about 30 minutes, about 1 minute to about 20 minutes, about 1 minute to about 10 minutes, about 1 minute to about 5 minutes, about 5 minutes to about 16 hours, about 5 minutes to about 14 hours, about 5 minutes to about 12 hours, about 5 minutes to about 10 hours, about 5 minutes to about 8 hours, about 5 minutes to about 6 hours, about 5 minutes to about 4 hours, about 5 minutes to about 2 hours, about 5 minutes to about 1 hour, about 5 minutes to about 50 minutes, about 5 minutes to about 40 minutes, about 5 minutes to about 30 minutes, about 5 minutes to about 20 minutes, about 5 minutes to about 10 minutes, about 10 minutes to about 16 hours, about 10 minutes to about 14 hours, about 10 minutes to about 12 hours, about 10 minutes to about 10 hours, about 10 minutes to about 8 hours, about 10 minutes to about 6 hours, about 10 minutes to about 4 hours, about 10 minutes to about 2 hours, about 10 minutes to about 1 hour, about 10 minutes to about 50 minutes, about 10 minutes to about 40 minutes, about 10 minutes to about 30 minutes, about 10 minutes to about 20 minutes, about 20 minutes to about 16 hours, about 20 minutes to about 14 hours, about 20 minutes to about 12 hours, about 20 minutes to about 10 hours, about 20 minutes to about 8 hours, about 20 minutes to about 6 hours, about 20 minutes to about 4 hours, about 20 minutes to about 2 hours, about 20 minutes to about 1 hour, about 20 minutes to about 50 minutes, about 20 minutes to about 40 minutes, about 20 minutes to about 30 minutes, about 30 minutes to about 16 hours, about 30 minutes to about 14 hours, about 30 minutes to about 12 hours, about 30 minutes to about 10 hours, about 30 minutes to about 8 hours, about 30 minutes to about 6 hours, about 30 minutes to about 4 hours, about 30 minutes to about 2 hours, about 30 minutes to about 1 hour, about 30 minutes to about 50 minutes, about 30 minutes to about 40 minutes, about 40 minutes to about 16 hours, about 40 minutes to about 14 hours, about 40 minutes to about 12 hours, about 40 minutes to about 10 hours, about 40 minutes to about 8 hours, about 40 minutes to about 6 hours, about 40 minutes to about 4 hours, about 40 minutes to about 2 hours, about 40 minutes to about 1 hour, about 40 minutes to about 50 minutes, about 50 minutes to about 16 hours, about 50 minutes to about 14 hours, about 50 minutes to about 12 hours, about 50 minutes to about 10 hours, about 50 minutes to about 8 hours, about 50 minutes to about 6 hours, about 50 minutes to about 4 hours, about 50 minutes to about 2 hours, about 50 minutes to about 1 hour, about 1 hour to about 16 hours, about 1 hour to about 14 hours, about 1 hour to about 12 hours, about 1 hour to about 10 hours, about 1 hour to about 8 hours, about 1 hour to about 6 hours, about 1 hour to about 4 hours, about 1 hour to about 2 hours, about 2 hours to about 16 hours, about 2 hours to about 14 hours, about 2 hours to about 12 hours, about 2 hours to about 10 hours, about 2 hours to about 8 hours, about 2 hours to about 6 hours, about 2 hours to about 4 hours, about 4 hours to about 16 hours, about 4 hours to about 14 hours, about 4 hours to about 12 hours, about 4 hours to about 10 hours, about 4 hours to about 8 hours, about 4 hours to about 6 hours, about 6 hours to about 16 hours, about 6 hours to about 14 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours, about 6 hours to about 8 hours, about 8 hours to about 16 hours, about 8 hours to about 14 hours, about 8 hours to about 12 hours, about 8 hours to about 10 hours, about 10 hours to about 16 hours, about 10 hours to about 14 hours, about 10 hours to about 12 hours, about 12 hours to about 16 hours, about 12 hours to about 14 hours, or about 14 hours to about 16 hours). In some embodiments, forming the hydrogel can include incubating the biological sample with the at least one monomer in the presence of at least one catalyst to polymerize the at least one monomer.
[0170] In some embodiments, forming a hydrogel comprises: (i) soaking the biological sample with at least one monomer: and (ii) polymerizing the at least one monomer in the presence of at least one catalyst. In some embodiments, hydrogel formation occurs within a biological sample. In some embodiments, a biological sample (e.g., tissue section) is embedded in a hydrogel. In some embodiments, hydrogel subunits are infused into the biological sample, and polymerization of the hydrogel is initiated by an external or internal stimulus. FIG. 10 provides a non-limiting workflow of a method for embedding a biological sample in a hydrogel for further downstream applications. As seen in FIG. 10, in some embodiments, the biological sample can be soaked in hydrogel monomer(s). In some embodiments, the biological sample can be pre-treated as needed for monomer embedding. Pre-treatment can include any useful reagent or process to provide a hydrogel embedded or hydrogel coated sample. Non-limiting pre-treatment can include treatment of a substrate to facilitate binding of the sample to the substrate (e.g., by use of a silane solution to treat a surface of the substrate), detergent (Tween20. tergitol, TritonXIOO) based treatments and decrosslinking of FFPE tissues to enhance tissue permeability to the monomer, binding of a hydrogel or a monomer to a biological sample (e.g.. by use of an acrylic ester), and the like.
[0171] The soaked biological sample can then be contacted to a catalyst in order to catalyze polymerization of the monomer(s), thereby embedding the biological sample in a hydrogel. The hydrogel embedded biological sample can be further permeabilized for downstream analyses, e.g., analyte capture, probe extension, second strand synthesis, cleavage of the captured ligation product, sequencing, as well as other processes described herein.
[0172] In some embodiments, forming a hydrogel comprises: (i) coating the biological sample with at least one monomer and at least one catalyst; and (ii) polymerizing the at least one monomer in the presence of the at least one catalyst. In some embodiments, the biological sample (e.g., tissue section) is coated in a hydrogel. FIG. 11 provides a nonlimiting workflow of a method for coating a biological sample in a hydrogel for further downstream applications. As seen in FIG. 11, in some embodiments, the biological sample can be coated with a hydrogel or a prepolymer solution including components for forming a hydrogel (e.g., a prepolymer solution including at least one monomer and at least one catalyst, such as any described herein). The biological sample is then incubated in the presence of a catalyst in order to catalyze polymerization of the monomer(s), thereby covering the biological sample in a hydrogel. The hydrogel coated biological sample can be additionally permeabilized for downstream analyses, e.g., analyte capture, probe extension, second strand synthesis, cleavage of the captured ligation product, sequencing, as well as other processes described herein.
[0173] A hydrogel can sw ell in the presence of w ater. In some embodiments, a hydrogel comprises a natural material. In some embodiments, a hydrogel includes a synthetic material. In some embodiments, a hydrogel includes a hybrid material, e.g., the hydrogel material comprises elements of both synthetic and natural polymers. Any of the materials used in hydrogels or hydrogels comprising a polypeptide-based material described herein can be used. Embedding or coating the sample in this manner ty pically involves contacting the biological sample with a hydrogel such that the biological sample becomes surrounded by and / or contained within the hydrogel. For example, the sample can be embedded by contacting the sample with a suitable polymer starting material (e.g., a monomer), and activating the polymer material to form a hydrogel. In some embodiments, the hydrogel is formed such that the hydrogel is internalized within the biological sample.
[0174] In some embodiments, the biological sample is immobilized in the hydrogel via crosslinking of the polymer material that forms the hydrogel. In some embodiments, cross-linkers and / or initiators are added to hydrogel subunits. Examples of cross-linkers include, without limitation, bis-acrylamide, bis-acrylate, and diazirine. Examples of initiators include, without limitation, azobisisobutyronitrile (AIBN), riboflavin, and L-arginine. Inclusion of crosslinkers and / or initiators can lead to increased covalent bonding between interacting biological macromolecules in later polymerization steps.
[0175] In some embodiments, hydrogels can have a colloidal structure, such as with agarose, or a polymer mesh structure, such as with gelatin. In some embodiments, the hydrogel is a homopolymeric hydrogel. In some embodiments, the hydrogel is a copolymeric hydrogel. In some embodiments, the hydrogel is a multipolymer interpenetrating polymeric hydrogel.
[0176] In some embodiments, some hydrogel subunits are polymerized covalently or physically cross-linked, to form a hydrogel network. For example, hydrogel subunits can be polymerized by any method including, but not limited to, thermal crosslinking, chemical crosslinking, physical crosslinking, ionic crosslinking, photo-crosslinking, free-radical initiation crosslinking, an addition reaction, condensation reaction, water-soluble crosslinking reactions, irradiative crosslinking (e.g., x-ray, electron beam), or combinations thereof. Techniques such as lithographic photopolymerization can also be used to form hydrogels. Cross-linking can be performed chemically and / or photochemically, or alternatively by any other hydrogel-formation method know n in the art. For example, the biological sample can be immobilized in the hydrogel by polyacry lamide crosslinking. Further, analytes of a biological sample can be immobilized in a hydrogel by crosslinking (e.g., polyacrylamide crosslinking). In some embodiments, the polymerization comprises ammonium persulfate (APS) initiator / tetramethylethylenediamine (TEMED)-based crosslinking. In some embodiments, the polymerization comprises Azo initiator-based crosslinking. Non-limiting examples of Azo initiators include, e.g., bis[2-(4.5-dihydro-lH-imidazol-2-yl)propan-2- yl]diazene;dihydrochloride (CAS No. 27776-21-2), and the like. In some embodiments, the polymerization comprises UV-based crosslinking.
[0177] The composition and application of the hydrogel to a biological sample typically depends on the nature and preparation of the biological sample (e.g., sectioned, nonsectioned, fresh-frozen tissue, type of fixation). A hydrogel can be any appropriate hydrogel where upon formation of the hydrogel on the biological sample the biological sample becomes anchored to or embedded in the hydrogel. Non-limiting examples of hydrogels are described herein or are known in the art. As one example, where the biological sample is a tissue section, the hydrogel can include a monomer solution and an ammonium persulfate (APS) initiator / tetramethylethylenediamine (TEMED) accelerator solution. As another example, where the biological sample consists of cells (e.g., cultured cells or cells disassociated from a tissue sample), the cells can be incubated with the monomer solution and APS / TEMED solutions. For cells, hydrogel are formed in compartments, including but not limited to devices used to culture, maintain, or transport cells. For example, hydrogels can be formed with monomer solution plus APS / TEMED added to the compartment to a depth ranging from about 0. 1 pm to about 5 mm.
[0178] In some embodiments, the monomer solution can include the at least one monomer. In some embodiments, the monomer solution can include the at least one monomer, wherein the at least one monomer is provided in the presence of a second monomer that is different than the at least one monomer. In some embodiments, the at least one monomer and / or the second monomer, if present, is provided as a monomer solution at a concentration of about 2% to about 25% (e.g., about 2% to about 20%, about 2% to about 15%, about 2% to about 10%, about 2% to about 8%, about 2% to about 6%, about 2% to about 4%, about 4% to about 25%, about 4% to about 20%, about 4% to about 15%, about 4% to about 10%, about 4% to about 8%, about 4% to about 6%, about 6% to about 25%, about 6% to about 20%. about 6% to about 15%, about 6% to about 10%, about 6% to about 8%, about 8% to about 25%. about 8% to about 20%, about 8% to about 15%, about 8% to about 10%, about 10% to about 25%, about 10% to about 20%, about 10% to about 15%, about 15% to about 25%, about 15% to about 20%. or about 20% to about 25%) in a solvent. In some embodiments, the at least one monomer can comprise an acrylamide, a bis-acrylamide, an acrylate, a methacrylate, a bisacrylate, an alginate, a glutaraldehyde, or an agarose. In some embodiments, the second monomer can comprise an acrylamide, a bis-acrylamide, an acrylate, a methacrylate, a bisacrylate, an alginate, a glutaraldehyde, an agarose. In some embodiments, the at least one monomer and / or the second monomer, if present, comprises an acrylamide, a bis-acrylamide, an acrylate, a methacrylate, a bis-acrylate, an alginate, a glutaraldehyde, an agarose, or a combination thereof.
[0179] In some embodiments, the at least one monomer and / or the second monomer, if present, is polymerized by at least one catalyst. In some embodiments, the at least one catalyst is provided in the presence of a second catalyst that is different than the at least one catalyst. In some embodiments, the at least one catalyst is provided as an accelerator solution. In some embodiments, the at least one catalyst and / or the second catalyst, if present, is provided as an accelerator solution at a concentration of about 0.01% to about 10% (e.g.. about 0.01% to about 8%, about 0.01% to about 6%, about 0.01% to about 4%. about 0.01% to about 2%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.01% to about 0.1%, about 0.01% to about 0.05%, about 0.05% to about 10%, about 0.05% to about 8%, about 0.05% to about 6%, about 0.05% to about 4%, about 0.05% to about 2%. about 0.05% to about 1%, about 0.05% to about 0.5%, about 0.05% to about 0. 1%, about 0.1% to about 10%, about 0.1% to about 8%, about 0.1% to about 6%, about 0.1% to about 4%, about 0.1% to about 2%, about 0. 1% to about 1%, about 0. 1% to about 0.5%, about 0.5% to about 10%, about 0.5% to about 8%. about 0.5% to about 6%. about 0.5% to about 4%, about 0.5% to about 2%, about 0.5% to about 1%, about 1% to about 10%, about 1% to about 8%, about 1% to about 6%, about 1 % to about 4%, about 1 % to about 2%, about 2% to about 10%, about 2% to about 8%, about 2% to about 6%, about 2% to about 4%, about 4% to about 10%, about 4% to about 8%, about 4% to about 6%, about 6% to about 10%, about 6% to about 8%, or about 8% to about 10%) in a solvent. In some embodiments, the at least one catalyst can comprise a free radical initiator, a redox molecule, or an adjunct catalyst. In some embodiments, the second catalyst can comprise a free radical initiator, a redox molecule, or an adjunct catalyst. In some embodiments, the at least one catalyst and / or the second catalyst, if present, comprises a free radical initiator, a redox molecule, an adjunct catalyst, or a combination thereof. In some embodiments, the at least one catalyst and / or the second catalyst, if present, comprises a halogen, an azo compound, a peroxide, a peroxy disulfate (e.g., ammonium persulfate (APS) or potassium persulfate (KPS)), an amine (e.g., tetramethylethylenediamine (TEMED) or dimethylaminopropionitrile (DMPN)), or a combination thereof.
[0180] Polymerization methods for hydrogel subunits can be selected to form hydrogels with different properties (e.g., pore volume, swelling properties, biodegradability, conduction, transparency, and / or permeability of the hydrogel). For example, a hydrogel can include pores of sufficient volume to allow the passage of macromolecules, (e.g.. nucleic acids, proteins, chromatin, metabolites, gRNA, antibodies, carbohydrates, peptides, metabolites, and / or small molecules) to / from the sample (e.g., tissue section). It is known that pore volume generally decreases with increasing concentration of hydrogel subunits and generally increases with an increasing ratio of hydrogel subunits to cross-linker. Therefore, a hydrogel composition can be prepared that includes a concentration of hydrogel subunits that allows the passage of such biological macromolecules.
[0181] In some embodiments, the porous hydrogel is a non-degradable hydrogel. In some embodiments, the non-degradable hydrogel comprises a non-cleavable linker (e.g., an alkylene or heteroalkylene group, as can be present in a polymerized form of bis-acrylamide). In some embodiments, the porous hydrogel is a degradable hydrogel. In some embodiments, the degradable hydrogel comprises a cleavable linker (e.g., an alkylene or heteroalkylene group including a cleavable region, as can be present in a polymerized form of cystamine bisacrylamide having a disulfide bond as a cleavable region that can be treated with a reducing agent to degrade the linker). In some embodiments, the cleavable region includes a peptide linkage that can be treated with a protease to degrade the linker.
[0182] In some embodiments, a hydrogel includes a linker that allows anchoring of the biological sample to the hydrogel. In some embodiments, a hydrogel includes linkers that allow anchoring of biological analytes to the hydrogel. In such cases, the linker can be added to the hydrogel before, contemporaneously with, or after hydrogel formation. Non-limiting examples of linkers that anchor nucleic acids to the hydrogel can include 6-((Acryloyl)amino) hexanoic acid (Acryloyl-X SE) (available from ThermoFisher, Waltham. MA). Label-IT Amine (available from MirusBio, Madison, WI) and Label X (Chen et al., Nat. Methods 13:679-684, (2016)).
[0183] In some embodiments, functionalization chemistry can be used. In some embodiments, functionalization chemistry includes hydrogel-tissue chemistry (HTC). Any hydrogel-tissue backbone (e.g., synthetic or native) suitable for HTC can be used for anchoring biological macromolecules and modulating functionalization. Non-limiting examples of methods using HTC backbone variants include CLARITY, PACT, ExM, SWITCH and ePACT. In some embodiments, hydrogel formation within a biological sample is permanent. For example, biological macromolecules can permanently adhere to the hydrogel allowing multiple rounds of interrogation. In some embodiments, hydrogel formation within a biological sample is reversible.
[0184] In some embodiments, the methods described herein can further comprise contacting the degradable hydrogel with a cleaving agent. In some embodiments, the methods further comprise (e.g., after permeabihzing the sample or capturing an analyte): contacting the degradable hydrogel with a cleaving agent (e.g., a reducing agent, such as dithiothreitol (DTT)). In some embodiments, additional reagents are added to the hydrogel subunits before, contemporaneously with, and / or after polymerization. For example, additional reagents can include but are not limited to oligonucleotides (e.g.. capture probes), endonucleases to fragment DNA, fragmentation buffer for DNA, DNA polymerase enzymes, dNTPs used to amplify the nucleic acid and to attach the barcode to the amplified fragments. Other enzymes can be used, including without limitation, RNA polymerase, transposase, ligase, proteinase K, and DNase. Additional reagents can also include reverse transcriptase enzymes, including enzymes with terminal transferase activity, primers, and switch oligonucleotides. In some embodiments, optical labels are added to the hydrogel subunits before, contemporaneously with, and / or after polymerization.
[0185] In some embodiments, HTC reagents are added to the hydrogel before, contemporaneously with, and / or after polymerization. In some embodiments, a cell tagging agent is added to the hydrogel before, contemporaneously with, and / or after polymerization. In some embodiments, a cell-penetrating agent is added to the hydrogel before, contemporaneously with, and / or after polymerization.
[0186] In some embodiments, a biological sample is embedded in a hydrogel to facilitate sample transfer to another location (e.g., to an array or a substrate). For example, archived biological samples (e.g., FFPE tissue sections) can be transferred from storage to a spatial array to perform spatial analysis. In some embodiments, a biological sample on a substrate can be covered with any of the prepolymer solutions described herein. In some embodiments, the prepolymer solution can be polymerized such that a hydrogel is formed on top of and / or around the biological sample. Hydrogel formation can occur in a manner sufficient to anchor (e.g., embed or coat) the biological sample to or with the hydrogel. After hydrogel formation, the biological sample is anchored to (e.g.. embedded in or coated with) the hydrogel, wherein separating the hydrogel from the substrate (e.g., glass slide) results in the biological sample separating from the substrate along with the hydrogel. The biological sample contained in the hydrogel can then be contacted with a spatial array, and spatial analysis can be performed on the biological sample.
[0187] Any variety of characteristics can determine the transfer conditions for a given biological sample. Non-limiting examples of characteristics likely to impact transfer conditions include the sample (e g., thickness, fixation, and cross-linking) and / or the analyte of interest (different conditions to preserve and / or transfer different analytes (e.g., DNA, RNA, and protein)).
[0188] In some embodiments, the hydrogel is removed after contacting the biological sample with the spatial array. For example, methods described herein can include an event-dependent (e.g., light or chemical) degradation or depolymerization of the hydrogel, wherein upon application of the event (e.g., external stimuli) the hydrogel degrades or depolymerizes. In one example, a biological sample can be anchored to a DTT-sensitive hydrogel, where addition of DTT can cause the hydrogel to degrade and release the anchored biological sample.
[0189] Hydrogels embedded within or coated on biological samples can be cleared using any suitable method. For example, electrophoretic tissue clearing methods can be used to remove biological macromolecules from the hydrogel -embedded sample. In some embodiments, a hydrogel-embedded sample is stored in a medium before or after clearing of hydrogel (e.g., a mounting medium, methylcellulose, or other semi-solid mediums).
[0190] In some embodiments, the hydrogel chemistry can be tuned to specifically bind (e.g., retain) particular species of analytes (e.g., RNA, DNA, protein, etc.). In some embodiments, a hydrogel includes a linker that allows anchoring of the biological sample to the hydrogel. In some embodiments, a hydrogel includes linkers that allow anchoring of biological analytes to the hydrogel. In such cases, the linker can be added to the hydrogel before, contemporaneously with, or after hydrogel formation. Non-limiting examples of linkers that anchor nucleic acids to the hydrogel can include 6-((acryloyl)amino) hexanoic acid (Acryloyl-X SE), Label-IT Amine and Label X (Chen et al., Nat. Methods 13:679-684, 2016). Non-limiting examples of characteristics likely to impact transfer conditions include the sample (e.g., thickness, fixation, and cross-linking) and / or the analyte of interest (different conditions to preserve and / or transfer different analytes (e.g., DNA, RNA, and protein)).
[0191] Additional methods and aspects of hydrogel are described for example in Chen et al.. Science 347(6221): 543-548, 2015, the entire contents of which are incorporated herein by reference.
[0192] Permeabilization of the biological sample
[0193] In some embodiments, the methods described herein can include a permeabilizing step that comprises contacting the porous hydrogel with a permeabilization agent. In some embodiments, the permeabilization agent diffuses through the porous hydrogel and permeabilizes the biological sample (e.g., tissue section) embedded or coated in the hydrogel. The analytes then diffuse into or through the hydrogel after exposure to the permeabilization agent. In such cases, the porous hydrogel can facilitate the diffusion of the analytes in the biological sample into the pores of the hydrogel. In some embodiments, the target analytes can diffuse through the permeabilizing agent soaked hydrogel and hybridize or bind the capture probes on the other side of the hydrogel.
[0194] In some embodiments, the biological sample can be permeabilized to facilitate transfer of analytes out of the sample, and / or to facilitate transfer of species (such as capture probes) into the sample. If a sample is not permeabilized sufficiently, the amount of analyte captured from the sample may be too low to enable adequate analysis. Conversely, if the tissue sample is too permeable, the relative spatial relationship of the analytes within the tissue sample can be lost. Hence, a balance between permeabilizing the tissue sample enough to obtain good signal intensity while still maintaining the spatial resolution of the analyte distribution in the sample is desirable.
[0195] In general, a biological sample can be permeabilized by exposing the sample to one or more permeabilizing agents. Suitable agents for this purpose include, but are not limited to, organic solvents (e.g., acetone, ethanol, and methanol), cross-linking agents (e.g., paraformaldehyde), detergents (e.g.. saponin, Triton X-100™, Tween-20™, sodium dodecyl sulfate (SDS), or any surfactant described herein), and enzymes (e g., trypsin, proteases (e.g., proteinase K). In some embodiments, the detergent is an anionic detergent (e.g., SDS or N- lauroylsarcosine sodium salt soludon). In some embodiments, the biological sample can be permeabilized using any of the methods described herein (e.g., using any of the detergents described herein, e.g., SDS and / or N-lauroylsarcosine sodium salt solution) before or after enzymatic treatment (e.g., treatment with any of the enzymes described herein, e.g., trypsin, proteases (e.g., pepsin and / or proteinase K)). In some embodiments, the permeabilization agent comprises proteinase K. In some embodiments, the permeabilization agent is provided in the presence of a buffer (e.g.. Tris, as well as any described herein), a surfactant (e.g.. an ionic surfactant, such as any described herein), a PEG (e g., any described herein), or a combination thereof.
[0196] In some embodiments, a biological sample can be permeabilized by exposing the sample to greater than about 1.0 w / v % (e.g., greater than about 2.0 w / v %, greater than about 3.0 w / v %, greater than about 4.0 w / v%, greater than about 5.0 w / v %, greater than about 6.0 w / v %, greater than about 7.0 w / v %, greater than about 8.0 w / v %, greater than about 9.0 w / v %, greater than about 10.0 w / v %, greater than about 11.0 w / v %, greater than about 12.0 w / v %, or greater than about 13.0 w / v %) sodium dodecyl sulfate (SDS) and / or N- lauroylsarcosine or N-lauroylsarcosine sodium salt. In some embodiments, a biological sample can be permeabilized by exposing the sample (e.g., for about 5 minutes to about 1 hour, about 5 minutes to about 40 minutes, about 5 minutes to about 30 minutes, about 5 minutes to about 20 minutes, or about 5 minutes to about 10 minutes) to about 1.0 w / v % to about 14.0 w / v % (e.g., about 2.0 w / v % to about 14.0 w / v %, about 2.0 w / v % to about 12.0 w / v %, about 2.0 w / v % to about 10.0 w / v %, about 4.0 w / v % to about 14.0 w / v %, about 4.0 w / v % to about 12.0 w / v %, about 4.0 w / v % to about 10.0 w / v %, about 6.0 w / v % to about 14.0 w / v %, about 6.0 w / v % to about 12.0 w / v %, about 6.0 w / v % to about 10.0 w / v %, about 8.0 w / v % to about 14.0 w / v %, about 8.0 w / v % to about 12.0 w / v %, about 8.0 w / v % to about 10.0 w / v %, about 10.0 % w / v % to about 14.0 w / v %, about 10.0 w / v % to about 12.0 w / v %, or about 12.0 w / v % to about 14.0 w / v %) SDS and / or N-lauroylsarcosine salt solution and / or proteinase K (e.g., at a temperature of about 4% to about 35 °C, about 4 ° C to about 25 °C, about 40C to about 20 °C, about 4 °C to about 10 °C, about 10 °C to about 25 °C, about 10 °C to about 20 °C, about 10 °C to about 15 °C, about 35 °C to about 50 °C, about 35 °C to about 45 °C, about 35 °C to about 40 °C, about 40 °C to about 50 °C, about 40 °C to about 45 °C, or about 45 °C to about 50 °C).
[0197] In some embodiments, the biological sample can be incubated with a permeabilizing agent to facilitate permeabilization of the sample. Additional methods for sample permeabilization are described, for example, in Jamur et al., Method Mol. Biol. 588:63-66, 2010, the entire contents of which are incorporated herein by reference.
[0198] In some embodiments, the permeabilizing step (c) of the methods described herein can further comprise removing the permeabilized biological sample from the substrate. In some embodiments, the removal of the biological sample can optionally be performed to remove all or a portion of the biological sample from the substrate. In some embodiments, the removal step includes enzymatic and / or chemical degradation of cells of the biological sample. For example, the removal step can include treating the biological sample with an enzyme (e.g., a proteinase, e g., proteinase K) to remove at least a portion of the biological sample from the substrate. In some embodiments, the removal step can include ablation of the tissue (e.g.. laser ablation).
[0199] In some embodiments, the permeabilized biological sample is removed from the substrate prior to the analyte, or the proxy thereof, hybridizing to the capture probe. In some embodiments, the permeabilized biological sample is removed from the substrate after the analyte, or the proxy thereof, hybridizes to the capture probe.
[0200] D. Kits
[0201] In some embodiments, also provided herein are kits that include one or more reagents to detect one or more analytes described herein. In some instances, the kit includes a spatial array comprising a plurality of capture probes, in which a capture probe comprises a capture domain and a spatial barcode and a capture moiety.
[0202] In some embodiments, the reagent can include a reagent medium. In some instances, a first reagent medium comprises at least one monomer (e.g.. any described herein) configured to be polymerized, thereby forming a porous hydrogel. In some instances, a second reagent medium comprises at least one catalyst (e.g., any described herein) configured to catalyze a polymerization reaction for forming the porous hydrogel. In some instances, a third reagent medium comprises a permeabilization agent (e.g.. any described herein).
[0203] In some embodiments, a kit can further include components for use with a first substrate and a second substrate. In some instances, a biological sample is placed on the first substrate, and the second substrate comprises a spatial array. Non-limiting examples of components for use with a first substrate and a second substrate include any described herein, such as an alignment mechanism.
[0204] In some embodiments, a kit can further include instructions for performing any of the methods or steps provided herein.
[0205] EXAMPLES
[0206] EXAMPLE 1 - cDNA footprint - Non-Degradable Hydrogel embedded FF mouse brain
[0207] A fluorescent cDNA footprint assay was performed for fresh frozen mouse brain tissue sections embedded in a non-degradable hydrogel. The hydrogel composition included 4% acrylamide (w / v) + 0.2% bis-acrylamide (w / v), wherein the catalyst to accelerate polymerization of the hydrogel monomers included 0.2% TEMED (w / v) and 0.2% APS (w / v). The substrate was then contacted with a permeabilization buffer including 30 mM Tris, 5% Sarkosyl (w / v), 8% PEG (w / v), and 1.32 mg / ml proteinase K, wherein each tissue section had different permeabilization time exposures (FIG. 12). There was no tissue removal before capture probe hybridization.
[0208] The fluorescent images of the cDNA footprints showed that the intensity of cDNA footprints in hydrogel embedded tissue sections were lower compared to control samples. The results also show that the hippocampus appears sharper in the hydrogel embedded samples, wherein the intensity of the cDNA footprint increases with permeabilization time exposure for the hydrogel embedded samples (FIG. 13).
[0209] A puncta fluorescent assay targeting the Proxl gene was performed with a cDNA footprint assay for fresh frozen mouse brain tissue. Magnified images showed that tissue debris could be non-specifically retaining capture probes resulting in more background puncta (FIG. 14).
[0210] EXAMPLE 2 - cDNA footprint - Non-Degradable Hydrogel embedded fresh frozen mouse brain with tissue removal
[0211] A fluorescent cDNA footprint assay was performed for fresh frozen mouse brain tissue sections embedded in non-degradable hydrogel. The hydrogel composition included 4% acrylamide (w / v) + 0.2% bis-acrylamide (w / v), wherein the catalyst to accelerate polymerization of the hydrogel monomers includes 0.2% TEMED (w / v) and 0.2% APS (w / v). The substrate was then contacted with a permeabilization buffer including 30 mM Tris, 5% Sarkosyl (w / v), 8% PEG (w / v), and 1.32 mg / ml proteinase K, wherein each tissue section had different permeabilization time exposures (FIG. 15). The mouse brain tissue was removed before capture probe hybridization by exposing the tissue sample to the permeabilization buffer at 56°C for 10 minutes.
[0212] The magnified images show that tissue removal improved image quality, wherein clear puncta enrichment can be seen that is consistent with the cDNA footprint data (FIG. 16).
[0213] EXAMPLE 3 - Degradable Hydrogel embedding of tissue with tissue removal
[0214] A fluorescent cDNA footprint assay was performed for fresh frozen mouse brain tissue sections embedded in degradable hydrogel, wherein the hydrogel composition included 4% acrylamide (w / v) + 0.2% bis-acrylamide (w / v) (Bis) monomers or 4% acrylamide (w / v) + 0.2% cystamine bis-acrylamide (w / v) monomers. The tissue sections were destained after hydrogel embedding, then washed twice in lx PBST for 1 minute. The tissue sections were soaked in monomers for 30 minutes at room temperature (4% acrylamide (w / v), 0.2% Bis (w / v), 2X SSC). A polymerization mix was then added, and the tissue sections were incubated at room temperature for 1 hour (Monomer + 0.3% APS (w / v) +0.3% TEMED (w / v)). The tissue sections were then contacted with a permeabilization buffer with or without PEG (FIG. 17).
[0215] The magnified fluorescent images show cDNA footprint fluorescence in hydrogel embedded tissue, wherein A1&A2 are control tissue samples that were not embedded in hydrogel (FIG. 18). Their cDNA footprint obtained after permeabilization of tissue appeared very7diffuse or spatially less accurate. B1-D2 are test tissue samples that were embedded in hydrogel.
[0216] Bl. B2. Cl samples in hydrogel were permeabilized for 20 minutes in a perm buffer that contains PEG (30 mM Tris, 5% Sarkosyl (w / v), 8% PEG (w / v), PK 1.32mg / ml). These samples resulted in a sharper or spatially more accurate cDNA footprint indicating the effectiveness of the hydrogel to suppress flow and diffusion of the analyte (e.g., RNA or oligo probe) being captured. C2. DI, D2 samples in hydrogel were permeabilized for 20 minutes in a perm buffer that does not contain PEG. (30mM Tris, 5% Sarkosyl (w / v), PK 1.32mg / ml). These samples also resulted in a sharper or spatially more accurate cDNA footprint indicating the effectiveness of the hydrogel to suppress flow and diffusion as well as demonstrate that such reduction in flow can be achieved even without PEG.
Claims
WHAT IS CLAIMED IS:
1. A method for identifying a location of an analyte in a biological sample, the method comprising:(a) contacting the biological sample with a substrate, wherein the substrate comprises a plurality of capture probes, and wherein at least one capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode;(b) forming a porous hydrogel within or surrounding the biological sample, thereby embedding the biological sample in the porous hydrogel or coating the biological sample with the porous hydrogel, thereby generating a biological sample / hydrogel complex;(c) permeabilizing the biological sample / hydrogel complex;(d) hybridizing the analyte, or a proxy thereof, to the capture domain of the at least one capture probe; and(e) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte or a proxy thereof from the biological sample, or a complement thereof, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample.
2. The method of claim 1, wherein the forming step (b) comprises contacting the biological sample with at least one monomer and at least one catalyst.
3. The method of claim 2, wherein the biological sample is contacted with the at least one monomer for a period from about 5 minutes to about 1 hour prior to providing the at least one catalyst.
4. The method of claim 2 or 3, wherein the forming step (b) further comprises contacting the biological sample with the at least one catalyst for a period from about 5 seconds to about 16 hours.
5. The method of claim 1, wherein the forming step (b) comprises:(i) contacting the biological sample with at least one monomer; and(ii) polymerizing the at least one monomer in the presence of at least one catalyst.
6. The method of claim 5, wherein the biological sample is contacted with the at least one monomer and the at least one catalyst simultaneously for a period from about 5 seconds to about 16 hours.
7. The method of claim 1, wherein the forming step (b) comprises:(i) coating the biological sample with at least one monomer and at least one catalyst; and(ii) polymerizing the at least one monomer in the presence of the at least one catalyst.
8. The method of any one of claims 1-7, wherein the at least one monomer is provided in the presence of a second monomer that is different than the at least one monomer.
9. The method of claim 8, wherein the at least one monomer and / or the second monomer, is provided as a monomer solution at a concentration of about 2% to about 25% in a solvent.
10. The method of claim 8 or 9, wherein the at least one monomer and / or the second monomer, comprises an acrylamide, a bis-acrylamide, an acry late, a methacrylate, a bis-acrylate. an alginate, a glutaraldehyde, an agarose, or a combination thereof.1 1. The method of any one of claims 8-10, wherein the at least one monomer and / or the second monomer, is polymerized by at least one catalyst.
12. The method of claim 11, wherein the at least one catalyst is provided in the presence of a second catalyst that is different than the at least one catalyst.
13. The method of claim 11 or 12, wherein the at least one catalyst and / or the second catalyst, is provided as an accelerator solution at a concentration of about 0.01% to about 10% in a solvent.
14. The method of any one of claims 11-13, wherein the at least one catalyst and / or the second catalyst, comprises a free radical initiator, a redox molecule, an adjunct catalyst, or a combination thereof.
15. The method of claim 14, wherein the at least one catalyst and / or the second catalyst comprises a halogen, an azo compound, a peroxide, a peroxy disulfate (e.g.. ammonium persulfate (APS) or potassium persulfate (KPS)), an amine (e.g., tetramethylethylenediamine (TEMED) or dimethylaminopropionitrile (DMPN)), or a combination thereof.1 . The method of claim 11, wherein the polymerization comprises ammonium persulfate (APS) initiator / tetramethylethylenediamine (TEMED)-based crosslinking.
17. The method of claim 11, wherein the polymerization comprises Azo initiator-based crosslinking.
18. The method of claim 11, wherein the polymerization comprises UV -based crosslinking.
19. The method of any one of claims 1-18, wherein the porous hydrogel is a non- degradable hydrogel.
20. The method of claim 19, wherein the non-degradable hydrogel comprises a non- cleavable linker (e.g., a polymerized form of bis-acrylamide).
21. The method of any one of claims 1-18, wherein the porous hydrogel is a degradable hydrogel.
22. The method of claim 21, wherein the degradable hydrogel comprises a cleavable linker (e.g.. a polymerized form of cystamine bis-acrylamide).
23. The method of claim 22, further comprising after the permeabilizing step (c) or the capturing step (d) contacting the degradable hydrogel with a cleaving agent.
24. The method of claim 23, wherein the cleaving agent comprises a reducing agent, wherein the reducing agent is dithiothreitol (DTT).
25. The method of claim 1, wherein the forming step (b) comprises incubating the biological sample with the at least one monomer in the presence of at least one catalyst to polymerize the at least one monomer.
26. The method of claim 1, wherein the permeabilizing step (c) comprises contacting the porous hydrogel with a permeabilization agent.
27. The method of claim 26, wherein the permeabilization agent comprises proteinase K.
28. The method of claim 27, wherein the permeabilization agent is provided in the presence of a buffer, a surfactant, a polyethyleneglycol, or a combination thereof.
29. The method of any one of claims 1-28, wherein the permeabilizing step (c) further comprises removing the permeabilized biological sample from the substrate.
30. The method of any one of claims 1-29, wherein the method further comprises one or more of the following:(i) contacting the substrate with a bind-silane solution prior to contacting step (a);(ii) contacting the biological sample with an acrylic acid ester prior to or after contacting step (a);(iii) destaining the biological sample, wherein the biological sample is previously stained prior to or after contacting step (a); and / or(iv) washing the biological sample with phosphate buffered saline with polysorbate 20 prior to or after forming step (b).
31. A method of reducing mislocalization of an analyte in a biological sample, the method comprising:(a) providing the biological sample on a substrate, wherein the substrate comprises a plurality of capture probes, and wherein at least one capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode;(b) contacting the biological sample with at least one monomer;(c) polymerizing the at least one monomer in the presence of at least one catalyst to form a porous hydrogel within or surrounding the biological sample, thereby generating an embedded biological sample in the porous hydrogel or coating the biological sample with the porous hydrogel, thereby generating a coated biological sample; and(d) permeabilizing the embedded biological sample or the coated biological sample to remove at least a portion of the biological sample and to allow the analyte, or a proxy thereof, in the biological sample to interact with the at least one capture probe of the plurality of capture probes, thereby reducing mislocalization of the analyte in the biological sample.
32. The method of claim 31, further comprising:(e) extending the at least one capture probe using the analyte, or a proxy thereof, as a template; and(1) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte or the proxy thereof from the biological sample, or a complement thereof, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample.
33. The method of claim 31, further comprising:(e) hybridizing a ligation product to the at least one capture probe, wherein the ligation product comprises a sequence that is substantially complementary to a sequence of the analyte in the biological sample; and(f) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte from the biological sample, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample.
34. A method for identifying a location of an analyte in a biological sample, the method comprising:(a) contacting the biological sample with a first substrate;(b) forming a porous hydrogel within or surrounding the biological sample, thereby embedding the biological sample in the porous hydrogel or coating the biological sample with the porous hydrogel;(c) aligning the first substrate with a second substrate comprising an array, such that at least a portion of the biological sample is aligned with at least a portion of the array, wherein the array comprises a plurality of capture probes, wherein at least one capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode;(d) capturing the analyte, or a proxy thereof, using the at least one capture probe when the biological sample is aligned with at least a portion of the array, ; and(e) determining (i) the spatial barcode or the complement thereof, and (ii) all or a portion of the analyte, or a proxy thereof, from the biological sample, or a complement thereof, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample.
35. The method of claim 34. wherein the capturing step (d) further comprises migrating the analyte, or the proxy thereof, from the biological sample to the array.
36. The method of claim 34, wherein the aligning step (c) comprises: mounting the first substrate on a first member of a support device, the first member configured to retain the first substrate; mounting the second substrate on a second member of the support device; applying a reagent medium to the first substrate and / or the second substrate; and operating an alignment mechanism of the support device to move the first member and / or the second member such that at least a portion of the biological sample is aligned with at least a portion of the array, and such that the portion of the biological sample and the portion of the array contact the reagent medium.
37. The method of claim 36, wherein the alignment mechanism is coupled to the first member, the second member, or both the first member and the second member.
38. The method of claim 36, wherein the alignment mechanism comprises a linear actuator, and optionally wherein:the linear actuator is configured to move the second member along an axis orthogonal to the plane or the first member and / or the second member, and / or the linear actuator is configured to move the first member along an axis orthogonal to the plane of the first member and / or the second member, and / or the linear actuator is configured to move the first member, the second member, or both the first member and the second member at a velocity of at least 0. 1 mm / sec, and / or the linear actuator is configured to move the first member, the second member, or both the first member and the second member with an amount of force of at least 0.1 lbs.
39. The method of claim 36, wherein at least one of the first substrate and the second substrate further comprise a spacer disposed on the first substrate or the second substrate, wherein when at least the portion of the biological sample is aligned with at least a portion of the array such that the portion of the biological sample and the portion of the array contact the reagent medium, the spacer is disposed between the first substrate and the second substrate and is configured to maintain the reagent medium within a chamber formed by the first substrate, the second substrate, and the spacer, and to maintain a separation distance between the first substrate and the second substrate, wherein the spacer is positioned to surround an area on the first substrate on which the biological sample is disposed and / or the array disposed on the second substrate, wherein the area of the first substrate, the spacer, and the second substrate at least partially encloses a volume comprising the biological sample.
40. The method of claims 34-39, wherein the capturing step (d) comprises contacting the biological sample with a reagent medium comprising a permeabilization agent, thereby permeabilizing the biological sample to allow the analyte, or the proxy thereof, in the biological sample to interact with the array.
41. The method of claim 40, wherein the permeabilization agent comprises a protease.
42. The method of claim 41, wherein the permeabilization agent is provided in the presence of a buffer, a surfactant, a polyethyleneglycol, or a combination thereof.
43. A kit comprising:(a) a spatial array comprising a plurality of capture probes, wherein at least one capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode;(b) a first reagent medium comprising at least one monomer configured to be polymerized, thereby forming a porous hydrogel;(c) a second reagent medium comprising at least one catalyst configured to catalyze a polymerization reaction for forming the porous hydrogel;(d) a third reagent medium comprising a permeabilization agent; and(e) instructions for performing the method of any one of claims 1 -42.
44. The kit of claim 43, further comprising:(f) a support device configured to retain a first substrate and a second substrate, wherein the biological sample is placed on the first substrate, and wherein the second substrate comprises the spatial array; and(g) an optional alignment mechanism on the support device to align the first substrate and the second substrate.
45. The kit of claim 43 or 44, wherein the at least one monomer comprises an acrylamide, a bis-acrylamide. an acrylate, a methacrylate, a bis-acrylate. an alginate, a glutaraldehyde, an agarose, or a combination thereof.
46. The kit of claim 45, wherein the at least one monomer is provided as a monomer solution at a concentration of about 2% to about 25% in a solvent.
47. The kit of any one of claims 43-46, wherein the at least one catalyst comprises a free radical initiator, a redox molecule, an adjunct catalyst, or a combination thereof.
48. The kit of any one of claims 43-47, wherein the at least one catalyst comprises a halogen, an azo compound, a peroxide, a peroxy disulfate (e g., ammonium persulfate (APS) or potassium persulfate (KPS)), an amine (e.g., tetramethylethylenediamine (TEMED) or dimethylaminopropionitrile (DMPN)), or a combination thereof.
49. The kit of claim 47 or 48, wherein the at least one catalyst is provided as an accelerator solution at a concentration of about 0.01% to about 10% in a solvent.
Citation Information
Patent Citations
Spatially addressable molecular barcoding
US10002316B2
Method and product for localized or spatial detection of nucleic acid in a tissue sample
US10030261B2
Multiplexed imaging of tissues using mass tags and secondary ion mass spectrometry
US10041949B2
In situ nucleic acid sequencing of expanded biological samples
US10059990B2
Protein retention expansion microscopy
US10317321B2
Cited By
Systems and methods for detecting analytes from captured single biological particles
US12265079B1
Methods, compositions, and kits for determining the location of an analyte in a biological sample
US12275988B2
Increasing efficiency of spatial analysis in a biological sample
US12286673B2
Modular assay support devices
US12287264B2
Methods for spatial analysis using proximity ligation
US12297486B2
